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Abstract 
Antibodies against the major Plasmodium falciparum (Pf) sporozoite surface protein, 
circumsporozoite protein (CSP), can mediate sterile immunity thereby preventing malaria 
disease symptoms as shown by passive transfer in animal models. However, protective anti-
CSP memory antibody responses are not efficiently induced by natural Pf exposure or 
vaccination. Affinity maturation, i.e. the diversification of antigen-activated naïve precursor B 
cells by a somatic immunoglobulin (Ig) gene mutation process and the subsequent selection of 
B cells expressing antigen receptors with improved antigen affinity in germinal center reactions 
is considered key to the formation of protective memory B cell responses. However, how the 
anti-PfCSP memory B cell response matures in humans is not known. To address this question, 
the clonal evolution of the human anti-Pf CSP memory B cell response over three successive 
controlled Pf infections under chemoprophylaxis was assessed at single cell level by high 
throughput paired full-length Ig gene sequencing and recombinant monoclonal antibody 
production. The work provides basic insights in the longitudinal development of human 
memory B cell responses and identified germline-encoded Ig gene features that were associated 
with high anti-CSP affinity and Pf inhibitory antibody activity. The clonal selection of germline 
B cells expressing such antibodies, rather than affinity maturation, was associated with high 
quality anti-PfCSP memory B cell responses. The data provide insights into the evolution of 
antibody response to a complex protein antigen during infection and a strong rational for the 
design of novel CSP immunogens to target naïve B cell precursors expressing potent anti-CSP 
antibodies for the induction of protective memory B cell responses by vaccination.  
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Zusammenfassung 
Antikörper gegen Circumsporozoite protein (CSP), ein Oberflächenantigen von Plasmodium 
falciparum (Pf),  können sterile Immunität hervorrufen und dadurch die Entwicklung von 
Malaria im Tierversuch verhindern. Im Menschen werden protektive B-Zell 
Gedächtnisantworten gegen CSP durch natürliche Malariaerkrankung bzw. Vakzinierung 
jedoch nur unzureichend erzeugt.  - Für die Entwicklung von Gedächtnis-B-Zellen stellt die 
Affinitätsreifung, welche durch somatische Immungobulin Hypermutation sowie der 
nachfolgenden Selektion von B-Zellen mit verbesserter Antigenaffinität charakterisiert ist, eine 
Schlüsselfunktion in der Generierung von protektiven Immunantworten dar. Wie 
Affinitätsreifung gegen CSP im Menschen stattfindet ist jedoch nicht bekannt. In dieser Arbeit 
wird die Affinitätsreifung von CSP Gedächtnis B-Zellen auf Einzelzellebene im Menschen 
über drei kontrollierte Infektionen mit Pf Sporozoiten unter Chemoprophylaxe untersucht. 
Durch Hochdurchsatz-Einzelzell-Sequenzierung der Immunoglobulin (Ig) gene loci und der 
Produktion von  rekombinanten monoklonalen Antikörpern gewährt diese Arbeit Einsicht in 
die Selektion und Affinitätsreifung von humanen Gedächtnis-B-Zell Antworten gegen 
komplexe Proteinantigene und identifiziert Keimbahn kodierte Immunglobulin 
Charakteristika, die mit hoher CSP-Affinität und Pf-Inhibition einhergehen. 
Überraschenderweise zeigen die Daten, dass initiale klonale Selektion von hochaffinen B 
Zellen eine weitaus wichtigere Rolle als Affinitätsreifung in dieser Infektion spielt. Diese 
Arbeit zeigt fundamentale Eigenschaften von humanen Gedächtnisantworten in einer 
komplexen Parasiteninfektion und liefert die Grundlage für ein mögliches Design von 
neuartigen Immunogenen um hoch-affine B-Zellen gegen CSP effizienter zu induzieren. 
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Abbreviations 
7AAD 7-Aminoactinomycin D 
ABTS 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) 
AID activation-induced cytosine deaminase 
AUC area under curve 
B cell bone marrow derived cell 
BCR B cell receptor 
BM bone marrow 
bp base pairs 
BSA bovine serum albumin 
CD cluster of differentiation 
cDNA complementary DNA 
CDR complementarity determining region 
CHMI controlled human malaria infection 
CSP circumsporozoite protein 
CSR class-switch recombination 
DENV Dengue virus 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DTT dithiothreitol 
E.coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EDIII Envelope domain III 
EEF exoerythrocytic form 
ELISA enzyme-linked immunosorbent assay 
Fab fragment antigen binding 
FACS fluorescence-activated cell sorting 
Fc fragment crystallizable 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FWR framework region 
GC germinal center 
gp140 glycoprotein 140 
h hour 
HC-04 cells human hepatocyte cells 
HEK cells human embryonic kidney cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human Immunodeficiency Virus 
HRP horseradish peroxidase 
Ig immunoglobulin 
i.v. intravenous 
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LB lysogeny broth 
LPS lipopolysaccharide 
MHC major histocompatibility complex 
min minute 
NANP repeat peptide consisting of asparagine-alanine-asparagine-proline 
OD optical density 
Pb Plasmodium berghei 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PEI polyetherimide 
Pf Plasmodium falciparum 
PFA paraformaldehyde 
Pb-PfCSP transgenic Pb expressing the CSP of Pf 
RHP random hexamer primers 
RNA ribonucleic acid 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute (medium) 
RT reverse transcriptase 
RTS,S R: stands for the central repeat region of Pf CSP  
T: stands for the T cell epitopes in the C-terminus of CSP 
S: stands for the hepatitis B surface antigen (HBsAg) 1  
sec second 
SHM somatic hypermutations 
T cell thymus derived cell 
Taq polymerase thermos aquaticus polymerase 
TFH T follicular helper cells 
TH T helper cells 
TB terrific broth 
TSR thrombospondin-like type I repeat 
ZIKV Zika virus 
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1. Introduction 
1.1 B cell mediated adaptive immunity: 
The key features of the adaptive immune response to infection or vaccination are antigen 
specificity and long-term immune memory. Those are achieved by recruiting antigen-specific 
cells from the diverse pool of T or B lymphocytes and differentiating them to memory cells for 
immune recall1.  
 
1.1.1 Diversity of the B cell antigen receptor 
A hallmark of the adaptive immune system is the diversity of antigen-receptors with every 
newly generated lymphocyte expressing a unique antigen-receptor. Antigen receptors are 
encoded by two genes and the receptor diversity relies on a random somatic gene recombination 
process that assembles both genes from a large number of small gene segments. Successful 
recombination of both genes leads to allelic exclusion, i.e. abrogation of the recombination 
process on the second chromosome, thereby ensuring the expression of only one kind of 
antigen-receptor. B cells undergo this process during their early development in bone marrow 
(BM) where they recombine variable (V), diversity (D) and joining (J) segments in the heavy 
chain locus and V and J segments in the light chain locus to form functional Ig heavy (IgH) 
and light (IgL) chain genes, respectively (Fig. 1). IgH and to lesser extent IgL gene segments 
are recombined in an imprecise fashion thereby increasing antigen-receptor diversity2,3. 
Further, IgL chain genes are generated from either of two light chain loci, Ig kappa (Igκ) and 
lambda (Igλ). In humans, the  
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large number of individual Ig gene segments and the imprecise assembly process5,6, together 
with IgL chain gene locus diversity generate a theoretical maximum diversity of 1012-14 
different antigen-receptor specificities, which exceeds the actual number of B cells present at 
a given time in the whole organism (1012)7,8. Antigen-receptor diversity is key to the successful 
generation of protective immune responses against the plethora of potential pathogens that may 
be encountered during lifetime. However, cells expressing autoreactive B cell antigen receptors 
(BCRs) on the cell surface, which comprise the Ig and the signalling molecules Igα and Igβ9, 
which are generated at high frequency due to the random nature of the Ig genes assembly 
process, are efficiently purged from the B cell pool at self-tolerance checkpoints in the BM and 
Figure 1. Immunoglobulin heavy and light chain gene recombination. In the heavy chain gene locus, 
random gene D and J segments recombine to form DJ which then recombines a random V gene segment to 
form VDJ. In the light chain locus, random V and J segments recombine to form VJ. Upon selection for being 
functional and non-autoreactive, they serve as BCRs of a mature naïve B cell. The figure is adapted from4.
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periphery10-14. Therefore, the repertoire of B cells that remains in the system to respond to 
antigens expressed by invading pathogens may be considerably smaller than theoretically 
predicted. However, the diversity is still too large to allow for precise direct measurements.  
 
1.1.2 B cell receptor: Structure and Function 
BCRs are composed of Y-shaped IgH and paired Igκ or Igλ light chain homodimers linked by 
disulphide bridges and the associated Igα and Igβ signalling molecules4. The BCR is anchored 
in the cell membrane via a short transmembrane domain of the IgH chains15. However, upon 
antigen-mediated activation, B cells can also produce soluble antigen-receptors referred to as 
antibodies, which are composed of only the Ig part and lack the transmembrane region due to 
alternative splicing16. Antibodies are the effector molecules of B cell (humoral) immune 
responses. They are the product of antibody-secreting cells and are found at high concentrations 
in blood but also at mucosal surfaces. Here, they bind antigen and mediate defined effector 
functions through their IgH chains that interact with Ig receptors expressed on other immune 
cells as well as non-immune cells. Structurally, two fragments of antibodies can be 
distinguished, the Fab (fragment, antigen binding), which corresponds in large to the arms of 
Y-shaped molecule and mediates antigen-binding, and the stem or Fc (fragment, crystallizable) 
part, which determines the IgH-encoded effector function (Fig. 2).  
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IgH chains come in different flavors that are encoded by one of the following seven gene 
segments: IGHM, IGHG1-4, IGHA1-2, IGHE, and IGHD and show different effector functions 
based on interactions with specific Fc receptors17,18. The antigen-binding variable regions of 
the IgH and IgL chain genes are encoded by the joined V(D)J and VJ region of the fully 
rearranged IGH and IGK or IGL genes and therefore show high sequence variability. 
Structurally, the variable regions of both chains are divided into alternating framework and 
complementarity determining regions (FWRs and CDRs, respectively) (Fig. 2). While the 
FWRs mostly offer the frame for the protein structure and are overall more conserved in their 
sequence, CDRs show high sequence variability and strongly engage into antigen recognition.  
 
1.1.3 B cell immune responses 
Developing B cells that successfully passed the self-tolerance checkpoints and matured in the 
spleen circulate through the secondary lymphoid organs11-14. BCR-mediated interactions with 
a cognate antigen lead to their activation, proliferation and differentiation into either antibody 
secreting cells or resting memory B cells. Antigen-activated B cells internalize their BCRs 
thereby taking up antigen that is bound to the BCR. The uptake of protein antigens leads to 
their processing into small peptides that will be loaded onto so-called Major Histocompatability 
complex II (MHC-II) molecules for display on the cell surface. MHC molecules that present 
Figure 2. IgG antibody structure. Two units of 
heavy chain-light chain heterodimers linked by 
disulphite bridges form a single antibody molecule. 
The complementarity determining regions (CDR) of 
heavy and light chain variable regions (VH and VL, 
respectively) are indicated in orange and green, 
respectively. Antibody is functionally divided into 
antigen binding Fab and constant fragment Fc. The 
figure is adapted from4. 
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these antigen peptides can be recognized by cognate T-helper cells (TH)19 (Fig. 3A). The direct 
interaction between B cells and TH cells in secondary lymphoid organs is essential to induce 
the formation of germinal center reactions20 (Fig. 3B). 
 
 
 
Germinal center reactions allow for the focused maturation of the B cell response to improve 
antigen-binding and thereby the quality of the humoral immune response by generating and 
selecting high-affinity antibody variants22,23. This process of affinity maturation is considered 
key for the development of potent long-lasting B cell memory to pathogens and has been shown 
to be essential for the induction of protective vaccine responses24. Germinal centers form in 
anatomically defined areas of secondary lymphoid organs, are clearly visible at around 6 days 
post primary immunization25 and divide into two zones of proliferating (dark zone) and non-
proliferating (light zone) cells26. Proliferating B cells in the dark zone are characterized by the 
somatic diversification of their Ig genes by random point mutations27 (Fig. 3C). This process 
of somatic hypermutation (SHM) is regulated by the enzyme, Activation induced cytidine 
Figure 3. B cell mediated immune response. A. In response to protein antigen stimulation antigen specific naïve 
B cells engage in T cell - B cell contact. B. Non-GC dependent class switching and antibody secretion of B cells. 
Secondary follicular formation results in the generation and seeding of an germinal center (GC) by B cells, TH cells 
and FDCs. C. GC reaction where B cells undergo affinity maturation through Ig gene diversification and selection 
by FDCs and TFH cells. Post GC, B cells differentiate into memory B cells or antibody secreting plasma cells. D. 
The memory B and TFH cells can take part in the secondary antigen encounter to seed new GCs. The figure is 
adapted from21 
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deaminase (AID)28. In vitro experimental conditions estimate the mutation rate of AID as 103 
per base pair per cell division, which is 106 fold higher than the normal somatic mutation 
rate29,30. The random point mutations generate B cells carrying variants of antibodies with 
altered or non-altered affinity.  The Ig gene diversified GC B cells move to the light zone and 
compete for antigen presented by follicular dentritic cells (FDCs) and for help by the follicular 
T helper set, a specialized subset of T-helper cells (TFH)20,31. FDCs form a reticular network 
and can display antigen for extended periods of time32,33. GC B cells capture the antigen 
presented by FDCs through their BCR and present the processed antigenic peptides on MHC-
II34,35. B cells with high affine antibodies compete better for antigens from the FDCs and will 
present more on MHC-II. This higher peptide-MHC-II density on the B cells with higher affine 
antibodies leads to the longest contact with the cognate TFH cells36,37. The limitation of the 
antigen presented by the FDCs and key survival signals provided by the TFH cells form the 
basis for antibody affinity maturation allowing the selection of B cells with high affine 
antibodies (Fig. 3C)20,38,39. The mentioned observations of GC dynamics come from extensive 
studies performed in the mouse model system40. The mechanistic details of the processes are 
less known in humans. The GC selection of high affine antibodies is extremely efficient for 
small molecules such as haptens22,23,41 but more complex for protein antigens. 
AID is not only essential to allow for affinity maturation through SHM, but also regulates class 
switch recombination (CSR), i.e. the exchange of Ig gene constant regions at genomic level. 
While AID catalyzes both, SHM and CSR, these processes can occur independently as both 
IGHM transcripts with SHMs42-45 and non-mutated class-switched transcripts are found in GC 
B cells31. Upon positive selection by TFH cells, B cells exit the GCs and differentiate into 
memory B cells or antibody secreting plasma cells. B cells carrying high affine antibodies are 
more likely to differentiate into plasma cells46, whereas B cells with relatively lower affine 
antibodies differentiate into memory B cells, however the proportion of memory B cell to 
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plasma cell output may change over the GC life-time47. Memory B cells are quiescent B cells 
and do not contribute directly to the production of secreted antibodies. However, upon 
secondary antigen exposure they can get readily activated by antigen to differentiate into 
plasma cells or enter GCs for further diversification and affinity maturation48 (Fig. 3D).  
 
1.2 Plasmodium falciparum: Infection and Life cycle 
 
Malaria in humans is a mosquito vector born disease caused by Plasmodium parasites. Of the 
different species that cause clinical infection in humans, Plasmodium falciparum (Pf), which 
is most endemic in sub-Saharan Africa, causes the most severe form of the disease resulting in 
high mortality50. During a blood meal, Pf infected mosquitoes deposit sporozoites in the human 
skin from where they migrate to the nearest blood vessel and eventually home to the liver51-54. 
In the liver, sporozoites penetrate fenestrated endothelial cells and Kupffer cells to finally infect 
hepatocytes for their further development and differentiation into blood stage parasites 
(merozoites)55,56. Upon hepatocyte rupture, merozoites are released into the blood stream and 
infect circulating erythrocytes. After undergoing 48 h exponential replication inside the 
erythrocytes, merozoites and additional waste products are released into the blood stream 
Figure 4. Plasmodium falciparum life cycle. Bite of the 
infected mosquito releases Pf sporozoites into the human 
host (1). The sporozoites travel to and infect hepatocytes 
(2) where they differentiate to merozoites (3). Once 
released from the hepatocytes (4), merozoites infect 
blood erythrocytes (5) and induce symptomatic malaria. 
The merozoites differentiate into female and male 
gametocytes (6) which when taken by the mosquitoes 
fertilize to form ookinete (7) and then oocyst (8) in the 
mosquito midgut. Upon oocyst differentiation, the 
resulting sporozoites travel to salivary gland (9) and are 
ready to be transmitted by the next mosquito bite (10).  
The figure is adapted from49. 
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causing symptomatic disease. Inside erythrocytes, merozoites undergo either asexual 
expansion or differentiation into sexual male and female gametocytes. The sexual stage 
gametocytes are taken up during a blood meal by the Anopheles mosquito, wherein they 
fertilize to form the so called ookinete. The ookinete penetrates between basal lamina and 
midgut epithelium and differentiates into oocyst and then subsequently into sporozoites. The 
sporozoites invade the mosquito salivary glands and are released in the human host during the 
next blood meal for completion of the parasite life cycle57,58. 
 
1.2.1 Immune response to malaria 
Wide range longitudinal studies in endemic areas reveal the acquisition of immunity to malaria 
disease with repeated parasite exposure59,60. This leaves newborns and young children at the 
most vulnerable end of the population, whereas adults encounter less severe forms of the 
disease61. The understanding for such phenomenon comes from the observation that the first 
parasite exposure, both in infants and humans with no previous exposure, almost always results 
in sickness. During the primary exposures, sudden systemic release of merozoites in the blood 
results in febrile illness. However, repeated parasite exposure over years generates antibody 
serum titers and controls the acute sickness62-67. While the immunity is established for 
homologous strains, several exposures with different strains build a broader, cross-strain 
immunity68,69. This however does not always guarantee sterile immunity, but rather prevents 
clinical illness and symptoms. The delay in the development of protective immunity and the 
lack of sterile immunity suggested that the immune memory formation is inefficient in malaria 
infection70-72. Contrary evidences for and against this suggestion have been reported and this 
conundrum underscores the pertinence to study the development of immune memory in malaria 
and how best to employ vaccines to meet that end. 
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1.2.2 Anti-sporozoite immunity and circumsporozoite protein 
Seminal works in the 1970s by Nussenzweig and colleagues showed that immunization of mice 
with radiation attenuated P. berghei sporozoites provided sterile immunity against live P. 
berghei sporozoite challenge, but not against blood stage parasites73. This work established that 
sterile protection could be achieved and the findings that were later confirmed in humans using 
different attenuation strategies by radiation and genetic or chemical attenuation. Incubation of 
sporozoites with serum samples from mice immunized with irradiated sporozoites induced the 
so-called antibody-mediated “circumsporozoite precipitation”. Nussenzweig et al., later 
identified circumsporozoite protein (CSP), initially referred to as Pb44, as the sporozoite 
surface protein that was targeted by the antibodies, thereby inducing the precipitation reaction 
and active parasite inhibition74-77.  
CSP is structurally arranged in three domains, the N-terminal domain, a central region 
composed predominantly of NANP repeating units, and a GPI linked C-terminal domain that 
adheres the protein to the sporozoite surface78 (Fig. 5). The N-terminal and C-terminal domains 
are polymorphic between different P. falciparum strains. In contrast, the central NANP repeat 
domain and  
       
 
immunodominant B-cell epitope is highly conserved and differs only in the number of 
repeating units79,80. Based on these findings, CSP has long been considered a promising subunit 
Figure 5. Schematic representation of PfCSP. PfCSP comprises of a signal peptide (SS), N-terminal domain, 
region I, NANP repeat units, and a C-terminal domain containing α-thrombospondin type-1 repeat (TSR), region 
II and a GPI anchor. The region constituting RTS,S vaccine is indicated by the black line. 
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vaccine candidate leading to the development of RTS,S AS01 (MosquirixTM), the leading 
malaria vaccine candidate. RTS,S contains 18.5 NANP repeat units and the entire C-terminal 
domain of CSP and aimed to induce protective humoral immune responses81 (Fig. 5). However, 
recent Phase III clinical trials in endemic regions showed overall low protective efficacy 
ranging from 25% to 55% and no long-term protection, suggesting that protective memory 
responses did not develop efficiently82,83.  
Objectives 
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2. Objectives 
The overall goal of the thesis was to characterize the clonal evolution of the human anti-CSP 
memory antibody response over repeated Plasmodium falciparum infections and to determine 
the quality of the response at monoclonal antibodies level along the following specific aims, 
1. To develop a high-throughput platform that would enable full length human 
immunoglobulin heavy and light chain gene (Ig) amplification from sorted single B 
cells compatible with direct cloning. 
2. To determine the Ig gene features and clonal evolution of CSP-reactive memory B cells 
and corresponding plasmablasts after three controlled human malaria infections by 
high-throughput paired Ig gene amplification and sequencing at single cell level. 
3. To assess the maturation of the anti-CSP memory B cell response over the repeated Pf 
infections by recombinant monoclonal antibody production and qualitative assessments 
of their CSP-reactivity as well as efficacy to inhibit Pf sporozoites. 
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3. Methods 
3.1 Single B cell sorting and Ig gene amplification 
Single cell Ig gene amplification and sequencing was performed using the protocols described 
here84,85. 
3.1.1 Fluorescence activated single cell sorting 
Frozen PBMCs from liquid nitrogen storage was collected right before processing of the 
samples. The frozen vials were immediately transferred to 37 ºC water bath for 45 seconds 
until the frozen contents starts thawing. Before completely thawed, the contents of the vial was 
quickly transferred to 45 ml of RPMI medium in a 50 ml falcon tube and mixed well to ensure 
complete thawing took place in the tube and the residual DMSO was immediately diluted in 
the medium. The tubes were centrifuged at 350 x g for 5 min and the supernatant was discarded. 
The cell pellet was resuspended in 1ml of the cold FACS buffer (1% FCS in PBS) and 
transferred to 1.5 ml micro centrifuge tubes. The tubes were centrifuged at 1160 x g for 5 min 
at 4 ºC and the cell pellet was kept on ice after discarding the supernatant. Using manufacturer's 
instructions, AlexFluor 647 Protein labeling kit (Molecular Probes) was used for fluorescent 
labeling of recombinant PfCSP (Protein Potential, LLC). The pellet was resuspended in 100 µl 
of 30 ng/µl of labeled PfCSP and kept on ice for 30 min. After incubation, 1 ml of FACS buffer 
was added to the cell staining solution and the tubes were centrifuged at 1160 x g for 5 min at 
4 ºC. After discarding the supernatant, the cell pellet was resuspended in 100 µl of the staining 
cocktail containing antibodies listed in Table 1 in FACS buffer and incubated on ice for 30 
min. U-266 (DSMZ) cell lines were used for testing IGHE primers. 
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Table 1. Fluorochrome labeled monoclonal antibodies used in flow cytometry. 
Mouse anti-
human antibody 
Clone Manufacturer Dilution used 
CD19-BV786 SJ25C1 BD Biosciences 1:10 
CD20-APC-H7 2H7 BD Biosciences 1:20 
CD27-PE M-T271 BD Biosciences 1:5 
CD38-FITC HIT2 BD Biosciences 1:5 
IgG-BV510 G18-145 BD Biosciences 1:20 
CD138-BV421 MI15 BD Biosciences 1:20 
CD21-PE-Cy7 Bu32 BioLegend 1:20 
 
After incubation, 100 µl of FACS buffer containing 7-aminoactinomycin (7-AAD) diluted to 
1:200 was added to the cell suspension in staining cocktail and incubated on ice for 10 min. 
The tubes were washed once and the cell pellet was resuspended in 300 µl of FACS buffer and 
filtered through FACS tubes. FACS AriaII (BD) with the FACSDiVa software version 8.0.1 
(BD) was used for analyzing the stained cell samples and single cell sorting. Single cells were 
selected using FSC and SSC height and width parameters. CSP binding memory B cells were 
defined as 7AAD- CD19+ CD27+ IgG+ CSP+, 7AAD- CD19+ CD27+ IgG CSP+ or 7AAD- 
CD19+ CD27- IgG+ CSP+ cell population. Plasmablasts were defined as 7AAD- CD19+ 
CD27+ CD38+ cell population. Due to the limitation of the samples, the above gates were 
defined using 100,000 recorded cells. The single cell sorting was performed using an OR gate 
set up between CSP memory B cells and plasmablasts. Index sorting option of the software 
was enabled during sorting, hence the sorted cells could be identified later for either of the two 
populations. The sorting was performed in 384well plates containing 2 µl of sort RHP mix 
above cooled sorting stage. The sort RHP mix consisted of NP-40 to enable cell lysis, DTT to 
denature RNA secondary structures, RNAsin as a RNAse inhibitor and RHP to bind to the 
RNA and prime reverse transcription.  
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Table 2. Concentration of the reagents used per well as sort RHP mix. 
Reagent Concentration Volume (µl) 
Nuclease free water - 1.4813 
PBS 10X 0.0500 
DTT 100mM 0.1000 
NP-40 10% 0.1375 
RHP 300 ng/µl 0.1375 
RNAsin 40 U/µl 0.0938 
Total  2.0000 
 
As soon as the sorting was finished, the plates were frozen down on dry ice to preserve the 
contents and transferred to -80 ºC freezer for long term storage.  
 
3.1.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR) mediated cDNA 
synthesis 
The frozen PCR plates were thawed on ice and incubated at 68 ºC for 60 sec to enable RNA 
secondary structure denaturation. After the incubation, the plates were brought back on ice and 
2 µl of RT master mix was added. The RT mix consisted of the following reagents,  1X RT 
buffer to provide ambient buffer condition, DTT for denaturing RNA secondary structures, 
dNTP for the synthesis reaction, RNAsin as RNAse inhibitor and monkey murine leukemia 
virus derived reverse transcriptase SuperScript III for the enzymatic reaction. The 
concentration used as are in the below table 3 and performed using the conditions listed in the 
table 4. 
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Table 3: Concentration of the reagents used per well as RT master mix for RT-PCR. 
Reagent Concentration Volume (µl) 
Nuclease free water - 0.6375 
RT buffer 5X 0.8000 
DTT 100mM 0.3000 
dNTP 25 mM each 0.1375 
RNAsin 40 U/µl 0.0563 
SuperScript III 200 U/µl 0.0688 
Total  2.0000 
 
Table 4. RT-PCR thermocycler program 
Step Temperature Duration Cycles 
RNA denaturation 42 ºC 5 min 1 
RHP annealing 25 ºC 10 min 1 
Reverse Transcription 50 ºC 60 min 1 
Ending reaction 94 ºC 5 min 1 
 
3.1.3 Amplification of Ig gene transcripts using nested PCR 
Ig gene amplification of heavy, kappa and lambda loci was performed using a nested PCR 
approach with primary and secondary PCRs for each locus84, 85. 1st PCR was performed using 
1 µl of cDNA template in three different PCRs, each with locus specific primer sets, listed in 
the supplementary table S3 and the reagent concentration in Table 5. The resulting amplicons 
of the primary PCR were used as template in the 2nd PCR, using the primer sets listed in 
supplementary table S3 and the reagent concentration in Table 6. Both forward and reverse 
primers used in the 2nd PCR were barcoded with 16bp and the barcoded primers were used 
along the row or column to have unique combination in each well. The conditions of both the 
PCRs are listed in Table 7. 
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Table 5. Concentration of the reagents used per well in 1st (1° PCR). 
Reagent Concentration Volume (µl) 
Nuclease free water - 7.5950 
Buffer 10X 1.0000 
5’ primer sets 50 µM 0.1300 
3’ primer sets 50 µM 0.1300 
dNTPs 25 mM each 0.1000 
HotStart Taq 5 U/µl 0.0450 
Template  1.0000 
Total  10.0000 
Table 6. Concentration of the reagents used per well in 2nd (2° PCR). 
Reagent Concentration Volume (µl) 
Nuclease free water - 7.7900 
Buffer 10X 1.0000 
5’ primer sets 50 µM 0.0325 
3’ primer sets 50 µM 0.0325 
dNTPs 25 mM each 0.1000 
HotStart Taq 5 U/µl 0.0450 
Template  1.0000 
Total  10.0000 
 
Table 7. 1st (1°) and 2nd (2°) thermocycler program for the three loci 
 Temperature   
Step Heavy Kappa Lambda Duration Cycles 
Activation of 
HotStart Taq 
94 °C 94 °C 94 °C 15 min 1 
DNA 
denaturation 
94 °C 94 °C 94 °C 30 sec 50 
Primer annealing 58 °C 58 °C 60 °C 30 sec 50 
Elongation 72 °C 72 °C 72 °C 55 sec (1°) or 
45 sec (2°) 
50 
End 
amplification 
72 °C 72 °C 72 °C 10 min 1 
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3.1.4 Next generation sequencing (NGS) and sequence analysis 
For a given locus, 1 µl of the 2nd PCR mixture per well was taken and pooled from all the 
wells processed. The pooled DNA was purified using PCR purification columns and later by 
running 2 % agarose gel using NucleoSpin® Gel and PCR Clean-up kit from Macherery-Nagel 
GmbH, following manufacturer’s instructions. The purified amplicons were sequenced using 
454 FLX+ sequencing (Roche) or MiSeq 300 bp Paired End (Illumina). The sequencing reads 
were processed through the published bioinformatics pipeline, sciReptor (version 1.0.1.‐1‐
gad8bbdf or 1.0.2‐0‐gf70a308). The pipeline assembled the reads based on the barcodes present 
in the 5’ and 3’, built consensus sequence and used standalone version of IgBLAST to extract 
the gene segment usage, somatic hypermuation count and position and CDR3 features. The 
pipeline also linked the index data to the sequences. Using MySQL and R scripts, specific 
queries were coded and executed to do the analysis on functional matching heavy and light 
chains. 
 
3.2 Ig gene cloning and monoclonal antibody expression 
3.2.1 Ig gene specific PCR 
To clone to the heavy and light chain gene sequences into the corresponding expression vectors, 
gene specific PCRs were performed. Based on the Ig gene analysis, specific V and J segment 
primers that carried restriction enzyme sites were used from the list available in the 
supplementary table S3. While the 5’ V gene primer for all loci used AgeI restriction site, 3’ J 
gene primers for heavy, kappa and lambda used SalI, BsiWi and XhoI restriction sites, 
respectively. 1st PCR product was used as a template and the concentration of other reagents 
are listed in the Table 8. The 2nd PCR program mentioned in the Table 7 was used for 
amplification.  
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Table 8. Concentration of the reagents used per well in Specific PCR. 
Reagent Concentration Volume (µl) 
Nuclease free water - 29.40 
Buffer 10X 4.00 
5’ primer sets 50 µM 2.00 
3’ primer sets 50 µM 2.00 
dNTPs 25 mM each 0.40 
HotStart Taq 5 U/µl 0.20 
Template  2.00 
Total  40.00 
 
3.2.2 Preparation of chemo-competent bacteria 
Escherichia coli DH10B strain was used in cloning. Frozen E.coli stock was streaked on a 
lysogeny broth (LB) agar plate and incubated at 37 °C overnight. Single colony from the LB 
plate was inoculated in a 5 ml LB medium and incubated at 37 °C in 180 rpm shaker overnight. 
800 µl of the overnight grown culture was given as inoculum to 250 ml of LB medium and 
incubated at 37 °C in 180 rpm shaker. Absorbance was measured until the culture reached 
OD600 0.5. The culture was then kept on ice for 30 min and centrifuged at 3000 rpm for 20 min 
at 0 °C. The bacterial pellet was resuspended in 80 ml of sterile 0.1 M CaCl2 and incubated on 
ice under cold condition overnight. Next day, the contents were centrifuged at 3000 rpm for 20 
min at 0 °C and the bacterial pellet was resuspended in 2 ml of 0.1 M CaCl2 with 15 % glycerol. 
Aliquots of 50 µl bacterial suspensions were made, quickly frozen using liquid nitrogen and 
transferred to – 80 °C freezer for long term storage. Competency of the bacteria was determined 
by transforming them using plasmid at the following concentration: 1 ng, 0.25 ng, 0.0625 ng, 
and 0.015625 ng. Bacteria were used only when they yielded >=106 colonies/µg of DNA. 
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3.2.3 Transformation of chemo-competent E. coli for cloning vector generation 
Igγ1, Igκ and Igλ vectors containing ampicillin resistance gene were used for cloning heavy, 
kappa and lambda genes, respectively (Supplementary Fig. S1). Frozen competent bacterial 
vials were incubated on ice for 20 min and thawed. To 10 µl of competent bacteria, 1 ng of 
cloning vector was added and incubated on ice for 20 min. After incubation, heat-shock was 
given by incubating the tubes at 37 °C for 2 min and bringing them back on ice for 5 min. After 
adding 100 µl of pre-warmed LB medium, the tubes were shaken at 650 rpm, 37 °C for 40 min. 
After incubation, 10 µl of the bacterial suspension was spread-plated in a LB agar plate 
containing ampicillin at 100 ng/µl and incubated at 37 °C overnight. Single bacterial colony 
from the plate was inoculated in 5 ml of LB medium containing 75 ng/µl ampicillin and 
incubated at 37 °C in 180 rpm overnight. 500 µl of the overnight grown culture was given as 
inoculum in 200 ml of LB medium containing 75 ng/µl ampicillin and incubated overnight at 
37 °C in 180 rpm. The bacterial culture was centrifuged at 3000 rpm for 10 min and the pellet 
was used for plasmid purification using NucleoBond® Xtra Midi/Maxi kit from Macherey-
Nagel GmbH following manufacturer’s instructions. DNA concentration of the vectors was 
measured using Nanodrop.  
 
3.2.4 Restriction endonuclease digestion of cloning vectors and PCR amplicons 
The cloning vectors and PCR amplicons were double digested using the enzymes 
corresponding to the locus. AgeI was used for all three loci, whereas SalI, BsiWI and XhoI 
were used for heavy, kappa and lambda loci, respectively. Double digest recommendations 
from New England Biolabs were followed and the digestions were performed at 37 °C for 2 
hr. After digestion of the PCR amplicons, the NucleoSpin® 96 PCR Clean-Up kit from 
Macherey-Nagel GmbH was used for purification. For the cloning vectors, the digested product 
was run 2 % agarose gel and the band corresponding to the linearized vectors were cut and 
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purified using the NucleoSpin® Gel and PCR Clean-up kit from Macherery-Nagel GmbH, 
following manufacturer’s instructions. The linearized vectors were aliquoted and frozen at -20 
°C freezer for long term storage. 
 
3.2.5 Ligation of the digested cloning vectors and PCR amplicons 
Digested and purified PCR amplicons were ligated to their corresponding linearized cloning 
vectors, using T4 DNA ligase. The reaction was performed as mentioned in the Table 9, and 
incubated overnight at 16 °C. After incubation, 6 µl of the ligation reaction mixture was mixed 
with 10 µl of chemo-competent bacteria and transformation was performed. 
Table 9. Concentration of the reagents used per reaction for ligation. 
Reagent Concentration Volume (µl) 
Digested PCR amplicon 6-15 ng/µl 7.5 
Ligation buffer 10X 1.0 
Linearized cloning vector 25 ng/µl 1.0 
T4 DNA Ligase 400 U/µl 0.5 
Total  10.00 
 
3.2.6 Screen for successful cloning by bacterial colony PCR and Sanger sequencing 
To assess for successful cloning, three bacterial colonies were randomly chosen from, and the 
presence of PCR amplicon ligated to the cloning vector was verified through PCR. The primers 
used for the PCR annealed to the vector constructs and hence the resulting amplicon size served 
as an indicator for the presence of ligated PCR amplicon. PCR master mix was prepared as 
mentioned in the Table 10. The bacterial colony touched by a pipette tip was immersed into 
the reaction mix for 5 min. The PCR was performed using the conditions listed in the Table 11.  
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Table 10. Concentration of the reagents used per well in bacterial colony PCR. 
Reagent Concentration Volume (µl) 
Nuclease free water - 18.6 
Buffer 10X 2.5 
5’ primer 50 µM 0.2 
3’ primer 50 µM 0.2 
dNTPs 1.25 mM each 2.5 
Taq polymerase 5 U/µl 1.0 
Total  25.0 
 
Table 11. Bacterial colony PCR thermocycler program 
Step Temperature Duration Cycles 
Activation of Taq 
polymerase 
94 ºC 5 min 1 
DNA denaturation 94 ºC 30 sec 72 
Primers annealing 58 ºC 30 sec 72 
Elongation 72 ºC 60 sec 72 
End amplification 72 ºC 10 min 1 
 
The size of the amplicons was assessed by running the products on 2% agarose gel. Successful 
amplified (~650 bp for Igγ1, ~700 bp for Igκ and ~590 bp for Igλ) products were commercially 
sequenced at Eurofins Genomics GmbH for sequencing service. The resulting sequences were 
compared to the secondary PCR sequences of the Ig genes. Sequences that showed any 
variation to the secondary PCR sequences were ignored from further analysis. 
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3.2.7 Preparation of cloned vector 
Bacterial colonies that were screened and selected for successful Ig gene cloning were 
inoculated in 5 ml LB medium containing 75 ng/µl ampicillin and incubated overnight at 37 
°C in 180 rpm shaker. After incubation, the bacterial culture was centrifuged at 4000 rpm for 
5 min and the pellet was used for isolation of vector using NucleoSpin® Plasmid Kit from 
Macherey-Nagel, following manufacturer’s instructions. Final elution of the vectors was 
performed using 150 µl Elution buffer and the DNA concentration was measured using 
Nanodrop. Until further use, the vectors were stored in -20 °C freezer. 
 
3.2.8. Germline reversion of Ig genes 
For the generation of germline reversion, Ig genes of all the mutated clusters members were 
aligned in Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo) and compared to the 
germline Ig gene downloaded from IMGT® (http://www.imgt.org/). The point mutations were 
reverted to the germline bp in the V regions. In the heavy chain CDR3 region, the most 
consensus bp at a given position from the cluster members was considered germline bp. In the 
light chain CDR3 region, the V and J sequences from the database was used for construction. 
The gene sequences carrying corresponding restriction sites were synthesized at MWG gene 
synthesis service and cloned into the corresponding cloning vector.  
 
3.2.9 FreeStyle™ 293-F cell culture 
FreeStyle™ 293-F cells were cultured using FreeStlye293 Expression Medium at 37 °C and 8 
% CO2 in 180 rpm shaker. The cells were seeded in 20 ml at 0.5 x 106 cells/ml in a 50 ml 
filtered culture tubes. The cells were regularly passaged when the cell count reached 3 x 106 
cells/ml. The passaging steps included pelleting down the cells at 1500 rpm for 5 min, 
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discarding the spent medium, resuspending the cell pellet in the fresh medium and seeding 
them at the above mentioned concentration. 
 
3.2.10 Cotransfection of FreeStyle™ 293-F cells using Polyethylenimine (PEI) 
10 ml culture of 1.5 x 106 cells/ml were seeded a day before transfection and allowed to grow 
at 37 °C and 8 % CO2 in180 rpm shaker. During the day of transfection, 15 µg of each heavy 
and light chain vectors were added to the culture and the tubes were placed back in the shaker 
for 10 min. After the incubation, 150 µl of 0.6 mg/ml sterile PEI was added to the culture and 
the tubes were placed back in the shaker. A day after the transfection, 10 ml of EX-CELL 293 
Medium complemented with L-Glutamine was added and the tubes were incubated in the 
shaker. 5 days post transfection, the cell culture tubes were centrifuged at 4000 rpm at 4 °C for 
30 min and the supernatant was carefully transferred into a clean tube. The antibody containing 
supernatants were stored at 4 °C, until further use. 
 
3.2.11 Purification of recombinant monoclonal antibodies 
Protein G Sepharose beads were used for purification of the recombinant antibodies. 100 µl of 
beads per 20 ml antibody supernatant was taken and washed with cold PBS. The beads were 
then added to the supernatant and mixed well by overnight incubation in tube rotator at 4 °C. 
After incubation, the tubes were centrifuged at 2000 rpm for 20 min at 4 °C and the supernatant 
was transferred to a clean tube. The pellet beads were resuspended in 1 ml cold PBS and 
transferred into equilibrated Biospin column. The beads were washed twice by letting 1 ml of 
cold PBS run through the column. The bound antibodies were thrice eluted using 200 µl of 
0.1M glycine (pH 3.0) and the eluent was collected in 20 µl of 1 M Tris (pH 8.0). The purified 
antibodies were dialyzed in cold PBS using using Slide-A-Lyzer® Mini Dialysis Devices 
following manufacturer’s instructions. 
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3.3 Biochemical and functional characterization of monoclonal antibodies 
3.3.1 Antibody concentration determination 
Concentration of the purified antibodies was determined using Enzyme Linked Immunosorbent 
Assay (ELISA). High binding 96 well ELISA plates were coated with 2 µg/ml goat anti-human 
IgG Fc-fragment in 50 µl/well of PBS at 4 °C overnight. The plates were washed with deionized 
water three times and 200 µl/well of PBS with 0.01% Tween and 0.01 M EDTA was added as 
blocking buffer and incubated at RT for 1 hr. 1:2.5 serial dilution of antibodies up to 8 steps 
were prepared in PBS with the starting dilution of 1 in 100. Purified human IgGs with known 
concentration was also similarly serially diluted to use as a standard with the starting 
concentration of 1 and 3 µg/ml. After blocking, the plates were washed thrice and incubated 
for 1.5 h with 50 µl /well the diluted antibodies and standard antibody. After incubation, the 
plates were washed thrice and incubated for 1 h with 50 µl/well of horseradish peroxidase 
conjugated goat anti-human IgG at 1 µg/ml in blocking buffer. The plates were washed and the 
bound antibodies were developed using 100 µl/well of ABTS 1-step solution (Roche) 
containing 1 µl/ml of H2O2. Absorbance was measured at OD405 using M1000 Pro platereader 
(Tecan) and the concentrations of the monoclonal antibodies were determined using the 
standard antibody absorbance. 
 
3.3.2 Antibody reactivity assessment 
High binding 96 well plates were coated with 40 ng/well CSP86 or 100 ng/well NANP10 (Alpha 
Diagnostic Intl. Inc.) at 100 µl/well in PBS overnight at 4 °C. After incubation, the plates were 
washed with three times with deionized water and incubated with 200 µl/well blocking buffer 
containing 1 % BSA in PBS for 1 h. The monoclonal antibodies were serially diluted 1:4 up to 
4 steps with the starting concentration 4 µg/ml in PBS. As positive and negative controls, the 
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monoclonal antibodies 2A1087 and mGO5388 were used. After blocking, the plates were 
incubated for 1.5 h with 50 µl/well of serially diluted antibodies. After incubation, the plates 
were washed thrice and incubated for 1 h with 50 µl/well of horseradish peroxidase conjugated 
goat anti-human IgG at 1 µg/ml in blocking buffer. The plates were washed and the bound 
antibodies were developed using 100 µl/well of ABTS 1-step solution (Roche) containing 1 
µl/ml of H2O2. Absorbance was measured at OD405 using M1000 Pro platereader (Tecan). The 
reactivity of the monoclonal antibodies to a given antigen was determined by calculating area 
under the curve of absorbance measured for the 4 dilutions using GraphPad Prism 6.07. 
 
3.3.3 Antibody poly-reactivity assessment 
High binding 384 well ELISA plates were coated with 15 µl of recombinant human insulin (10 
µg/ml), dsDNA (10 µg/ml) or LPS (5 µg/ml) at 4 °C overnight. The plates were washed thrice 
with deionized water and blocked with 50 µl/well blocking buffer (PBS with 0.01% Tween 
and 0.01 M EDTA) for 1 hr. After incubation, plates were thrice washed and incubated for 1.5 
h with 15 µl of monoclonal antibodies at 4 µg/ml in PBS. Antibodies ED3889 and mGO5388 
were used positive and negative controls. After incubation, the plates were washed thrice and 
incubated for 1 h with 15 µl/well of horseradish peroxidase conjugated goat anti-human IgG at 
1 µg/ml in blocking buffer. The plates were washed and the bound antibodies were developed 
using 25 µl/well of ABTS 1-step solution (Roche) containing 1 µl/ml of H2O2. Absorbance was 
measured at OD405 using M1000 Pro platereader (Tecan). The reactivity of the monoclonal 
antibodies to a given antigen was determined by absorbance measured and analyzed using 
GraphPad Prism 6.07. 
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3.3.4 Serum ELISA 
High binding 96 well plates were coated with 40 ng/well CSP at 100 µl/well in PBS overnight 
at 4°C. After incubation, the plates were washed with three times with deionized water and 
incubated with 200 µl/well blocking buffer containing 4 % BSA in PBS for 1 h. Serum samples 
were serially diluted 1:2 up to 4 steps with the starting concentration 1:100 in 2 % BSA in PBS. 
After blocking, the plates were incubated for 1.5 h with 50 µl/well of serially serum samples. 
After incubation, the plates were washed thrice and incubated for 1 h with 50 µl/well of 
horseradish peroxidase conjugated goat anti-human IgG at 2 % BSA in PBS. The plates were 
washed and the bound antibodies were developed using 100 µl/well of ABTS 1-step solution 
(Roche) containing 1 µl/ml of H2O2. Absorbance was measured at OD405 using M1000 Pro 
platereader (Tecan). The reactivity of the serum samples to CSP was determined by calculating 
area under the curve of absorbance measured for the 4 dilutions using GraphPad Prism 6.07. 
 
3.3.5 Surface Plasmon Resonance (SPR) 
SPR measurements were carried out in a BIACORE T200 (GE Healthcare) machine docked 
with a series S CM5 sensor chip (GE Healthcare). 10mM HEPES buffer with 150mM NaCl, 
0.02 % Tween 20 and 0.05 % BSA at pH 7.4 was used as a running buffer. Using 
manufacturer’s instructions, anti-human IgG antibody from the human antibody capture kit 
(GE Healthcare) was immobilized on the chip through amine-coupling. Antibody and control 
antibody mGO53 were captured in the sample and reference flow cell at equal concentration, 
respectively. After capture, both the flow cells were stabilized for 20 min at 10 µl/min flow 
rate. NANP5 resuspended in the running buffer was injected into the flow cell at different 
concentrations in the order, 0, 0.015, 0.09, 0.55, 3.3 and 20 μM. Each injection followed 60 s 
association and 180 s dissociation at the flow rate of 30 µl/min at 25 °C. After each run, both 
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the flow cells were regenerated using 3M MgCl2. BIACORE T200 software V2.0 was used for 
fitting the data in 1:1 binding model and performed steady state or kinetic analysis. 
 
3.3.6 Sporozoite hepatocyte traversal assay 
Human hepatocyte cell line (HC-04)90 cells were seed in a 96 well plate at 6 x 104 cells/well in 
a volume of 150 µl/well and incubated at 37 °C and 5 % CO2 for 24 h, until they reached 70 % 
confluency. 100,000 Pf NF54 sporozoites isolated from infected Anopheles coluzzi were 
incubated with 100 µg/ml monoclonal antibody in a volume of 27.5 µl on ice for 30 min. 27.5 
µl of 1 mg/ml Dextran-rhodamine (Molecular Probes) was added to the sporozoites antibody 
mixture and 50 µl of this mixture was added to the cells. The cells treated with just dextran-
rhodmine were used to measure the background noise. The cells treated with sporozoites and 
dextran-rhodamine were used for estimating the maximal traversal rate achieved. Monoclonal 
antibodies 2A1087,91 and mGO5388 were used as positive and negative controls, respectively. 
The plate was centrifuged at 3000 rpm for 10 min with no brakes and acceleration. After 
centrifugation, the plate was incubated at 37 °C and 5 % CO2 for 2 h. After incubation, the cells 
in the plate were washed thrice with PBS and the detached using trypsinization and 
resuspended in 10% FCS in PBS. The contents were transferred into micro centrifuge tubes 
and centrifuged at 3600 rpm for 5 min at 4 °C. The cell pellet was resuspended in 1 % PFA in 
PBS. Flow cytometry was performed in LSR II instrument and the frequency of dextran-
positive cells was estimated. After background noise detection, the inhibition of sporozoite 
traversal rate was estimated by normalizing the data to the maximal traversal rate achieved 
without antibody91. The data was analyzed in FlowJo V.10.0.8 (Tree Star). 
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3.4 Statistical analysis 
Experimental data were analyzed on RStudio (version 3.2.2) or Prism 6.07 (GraphPad) using 
two-tailed Mann-Whitney assuming non-normal distribution, Chi‐square test or Fisher’s exact 
test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. All experiments were performed 
in independently performed replicates, a minimum of twice. 
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4. Results 
4.1 Ig PCR primer establishment and validation  
To develop a high throughput strategy for the human Ig gene amplification using a barcoded 
primer matrix, primers used in Ig gene amplification were altered to use minimum primers at 
the barcoding 2nd PCR step. In the IGH PCRs, the newly designed primer sets with 9 IGHV 
gene primers in the 1st PCR and a single IGHV gene primer in the 2nd PCR (Complete mix)85 
were compared to the published primer sets (Tiller et al)84. PCRs performed on single cell 
sorted IgG+ CD27+ memory B cells from healthy donors showed comparable amplification 
efficiency for both primer sets (Fig. 6A). To enable parallel amplification of the different 
isotypes in one PCR plate, performance of IGHC primers of the isotypes, IgM, IgG, IgA and 
IgE were compared in isolation (specific) or as a mixture (MEGA) in amplifying B cells of the 
corresponding isotypes. Comparable amplification efficiency indicated that the constant 
primers did not sabotage amplification of one another and could be used as a mixture (Fig. 6B). 
Similar to IGH PCRs, 2nd PCR primers in the IGL PCRs were reduced to two and the resulting 
IGL PCR amplification efficiency of ~30 % and the overall IGK/IGL PCR efficiency of ~ 80 
% validated the primer sets (Fig. 6C). 
 
To summarize, the primers for Ig gene amplification designed to have minimum primer 
numbers at the barcoding steps amplified Ig genes with efficiency comparable to the published 
primer sets. 
 
Figure 6. Comparison of Ig PCR 
primers. A. IGH PCR amplification 
efficiency using published primer sets 
(Tiller et al) and primer sets developed 
(Complete mix). B. IGH PCR efficiency 
using specific or mixed (MEGA) constant 
primers. C. PCR efficiency of IGK and 
IGL PCRs and the overall light chain PCR 
efficiency. Red line indicates mean. This 
figure is adapted from85. 
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4.2 Performance of high-throughput matrix PCR 
To test the performance of the human matrix PCR, the 2nd PCR primers were barcoded using 
16 bp and were assigned to an individual row and column in a matrix, thus the individual 
reaction in each well would have a combination of uniquely barcoded forward and reverse 
primers85,92. IgG memory B cells from three healthy donors were single cell sorted and the 
barcoded primer matrix was used to amplify Ig genes. This strategy resulted in the 
amplification efficiency of 41%, 49% and 30% in heavy, kappa and lamdba PCRs. Taken 
together, 41% of the sorted cells were successfully amplified and sequenced in both heavy and 
light chain loci (Fig. 7A). 
 
During the primer establishment, the 1st PCR was deduced to be crucial in the amplification 
step for Ig heavy genes85. Ig gene analysis of the resulting sequences showed results 
comparable to the previously published data (Supplementary Fig. S2). To boost the overall 
amplification efficiency, an additional booster 1st heavy PCR was performed. The amplicons 
from the two first PCRs were pooled and used as template for the second PCR. Under a single 
booster or two booster PCRs, overall Ig heavy gene amplification efficiency increase by an 
Figure 7. Ig gene PCR 
results. A. Heat map 
illustrating PCR + (black) or 
PCR – (white) in IGH, IGK 
and IGL PCRs with the noted 
overall amplification 
efficiency from healthy 
donors HD1-3. B. PCR 
efficiencies using single 
(regular) or booster 1st PCRs. 
Red line indicates mean. 
This figure is adapted 
from85. 
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average of ~20 % and ~25 %, respectively, compared to a single 1st PCR (Fig. 7B). Based on 
this observation, all further matrix PCRs employed two 1st PCRs and pooling them as template 
for a single 2nd PCR in heavy PCR, whereas the kappa and lambda chain PCRs were performed 
without repetition. 
 
4.3 Controlled human malaria infection (CHMI) study cohort and sample collection 
In the PfSPZ-CVac clinical trial TÜCHMI-2, 9 malaria naïve donors were recruited for the 
controlled human malaria infection93. The donors were infected three times with live 5.12 x 
104 Pf NF54 sporozoites intravenously with an intervening period of 4 weeks. From the 
beginning of the trial period, the donors received nine doses of 5mg/kg chloroquine on a weekly 
basis as chemoprophylaxis against the Pf blood stage parasites (Fig. 8). 10 weeks after the third 
infection, the donors were challenged with 3.2 x 103 Pf NF54 sporozoites without chloroquine  
 
 
chemoprophylaxis and none of them developed blood parasitemia, indicating the establishment 
of sterile immunity. This thesis is based on the analysis performed on the samples collected 
from all donors at day 7 post each of the three controlled infections and challenge and the data 
analysis corresponding to the mentioned time periods will be referred to as I, II, III and C, 
respectively. 
 
Figure 8. CHMI scheme. Pictorial representation of 
the trial scheme93. Malaria naïve human donors 
received three doses of 5.12 x 104 Pf sporozoites 
(PfSPZ) at the interval of 4 weeks under choloroquine 
chemoprophylaxis. Blood samples taken on day 7 post 
three infections (I, II and III) were analyzed and 
presented in this thesis. Green arrows and black arrows 
indicate the chloroquine and PfSPZ injection, 
respectively. Red arrows indicate the blood sample 
collection time points.  
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4.4 Anti-CSP serum response in CHMI 
To understand the strength and the isotype usage of the CSP antibody response, serum collected 
from day7 post three infections of all 9 donors were assessed for CSP binding. Anti-CSP 
antibodies on day7 post first infection were undetectable in serum of all donors, indicating that 
in malaria naïve donors, a time span of seven days was too short to elicit detectable anti-CSP 
serum antibodies. However, at day7 post second infection, increased anti-CSP serum 
antibodies were found in T2_072 and T2_073 as IgM and T2_072 and T2_052 as IgG. Notably 
donor T2_072 also mounted strong anti-CSP IgA antibodies. In response to the third infection, 
all donors but T2_052 mounted anti-CSP IgM antibodies, albeit to various degrees. 5 out of 9 
donors showed 
                   
 
a clear increase in anti-CSP IgG antibodies, whereas only two donors showed an increase in 
anti-CSP IgA antibodies. Although all donors showed an increase in anti-CSP serum antibodies 
over the course of three infections, there was a greater diversity in the strength and the isotypes 
detected.  
 
4.5 Anti-CSP memory B cell and plasmablast response in CHMI 
To characterize the frequency of CSP reactive memory B cells, flow cytometry was performed 
using the peripheral blood mononucleocytes (PBMCs) isolated on day7 post three infections. 
Figure 9. Serum anti-CSP antibodies. Serum ELISA results representing the detection of CSP binding serum 
antibodies of the isotypes IgA, IgG and IgM. Day 7 post each of the three infections are indicated as I, II and III. 
The individual donors are indicated in different colors.
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Recombinantly expressed PfCSP was labelled with the fluorochrome Alexa 647 and used as a 
bait to detect CSP reactive memory B cells. After exclusion of dead cells using 7-AAD staining, 
live cells showing CD19 and CSP positivity with CD27 and/or IgG positivity were defined as 
CSP reactive memory B cells (Fig. 10A). Compared to non-infected malaria naïve donors, Pf 
infected donors showed significantly higher mean CSP reactive memory B cells frequency 
(Fig. 10B). However, CSP reactive memory B cell frequency showed greater variability among 
the 9 donors. Post three infections, three donors showed a strong CSP reactive memory B cell 
response mounting to >1% of all memory B cells, whereas three donors showed moderate 
response with ~1% of all memory B cells and three donors showed only weak response. It is 
noteworthy that in response to three infections, all 9 donors mounted CSP reactive memory B 
cell with frequencies greater than the observed mean CSP reactive memory B cell frequency 
in naturally exposed semi-immune African adults (0.14%)91. 
 
Independently, the frequency of plasmablasts in response to the Pf infections was estimated 
using CD27 and CD38 upregulation in live B cells (Fig. 10A). Interestingly, non-infected 
malaria naïve donors already had a mean plasmablast frequency of 0.6% among all B cells, 
Figure 10. CSP memory B cell and 
plasmablasts frequency post Pf 
infection. A. Flow cytometry gates 
illustrating CSP binding memory B 
cells (top: 7AAD- CD19+ CSP+ B 
cells positive for CD27 and/or IgG) 
and plasmablasts (bottom: 7AAD- 
CD19+ CD27+ CD38+ B cells) in Pf 
infected donor (left) in comparison to 
non-infected donor (right). B. 
Frequency of CSP memory B cells 
(top) and plasmablasts (bottom) at d7 
post three infections in 9 donors 
compared to non-infected healthy 
donors. **P<0.001, ****P<0.0001; 
two tailed Mann-Whitney test. 
.  
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indicating the ongoing background B cell response in otherwise healthy adults. However, the 
Pf infected donors showed a significantly increased mean plasmablast frequency, compared to 
healthy adults (Fig. 10B).  Similar to the CSP reactive memory B cells, the donors also showed 
greater variability in the plasmablast frequencies.   
CSP reactive memory B cells and activated plasmablasts from day7 post three successive 
infections were single cell sorted. Index sorting function was used to record the fluorescent 
parameter of the individual cells that were sorted. The established high-throughput PCR 
strategy was used in single B cell Ig gene amplification85. The resulting amplicons were pooled 
and bulk sequenced using either 454-sequencing or Miseq Illumina sequencing platforms. The 
sequences were mapped to the wells and analyzed for Ig gene features using the published 
immune repertoire analysis platform, sciReptor94. B cells with the functional Ig heavy and light 
chains were further analyzed. 
 
4.6 Ig heavy constant distribution  
To assess the isotype distribution of CSP memory B cells in CHMI, IGHC regions of the 
functional Ig genes were identified and annotated for different constant genes (Fig. 11). While 
CSP memory B cells post first Pf infection predominantly carried IGHM genes in all donors, 
IGHG and IGHA CSP memory B cells were also observed. This indicates the recruitment of 
pre-existing class-switched and IgM memory B cells into the primary response against CSP. 
Surprisingly, post second and third infection, IGHM was still predominant in CSP memory B 
cells, whereas an increase in IGHG genes was found only in a subset of donors. This could be 
explained by the continuous recruitment of naïve B cells or IgM memory B cells. Taken 
together, CSP memory B cell response in CHMI was predominantly mediated through Ig genes 
carrying IGHM. 
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In contrast to CSP memory B cells, plasmablast response against Pf infection in all donors was 
diverse throughout all three constants (Fig. 11). No significant difference in the frequencies of 
constant regions was observed in the plasmblasts over the course of three infections, indicating 
a broad response against several Pf antigens, presumably with minimal background response.  
 
4.7 Somatic hypermutation distribution  
To understand the naïve or memory status of the B cells isolated, SHM counts in the IGHV 
genes were analyzed and compared to the known published sequences. Given the trial donors 
were diagnosed to be malaria naïve, the CSP memory B cells post first infection were expected 
to derive from a naïve B cell pool that carried little somatic hypermutations. Surprisingly, the 
B cells post first infection carried several mutations with an average of 10 mutations in IGHV 
genes (Fig. 12A). This SHM load is comparable to that of the reported resting memory B cell 
populations from healthy adults95-98. Together with the Ig gene constant regions distribution, 
the SHM counts also indicate the recruitment of pre-existing memory B cells during primary 
Pf infection.  While the mean SHM count went down in response to the second and third 
infection, B cells with highly mutated antibodies were still observed (Fig. 12B). This indicates 
the continual recruitment of pre-existing memory B cells in the anti-CSP B cell response.  
Figure 11. Ig heavy constant usage. 
Frequencies of three major IgH 
constants in CSP memory B cells (top) 
and plasmablasts (bottom) post three 
infections as identified by the PCR 
amplified IGHV sequence. The donors 
are indicated in different colors. 
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To compare the relative recruitment of naïve and memory B cells, the B cell frequency with a 
SHM count less than or equal to 5 in IGHV genes was estimated for all donors post each of the 
three infections (Fig. 12C). In all donors except T2_051, the frequency of B cells with low 
mutated antibodies was increased due to the enhanced recruitment and acquisition of mutations 
Figure 12. Somatic hypermutation (SHM) analysis in IGHV genes. A. Overall SHM counts per IGHV gene in 
CSP memory B cell (top) and plasmablast (bottom) antibodies of all donors post three Pf infections. B. Mean SHM 
counts/IGHV gene of CSP memory B cell and plasmablast antibodies isolated for each donor, indicated in different 
colors. C-D. Frequency of IGHV genes carrying < = 5 SHM counts in each donor (C) and their isotype distribution 
(D) in CSP memory B cells. E. SHM counts per IGHV gene of antibodies carrying indicated isotypes or subclasses 
in CSP memory B cells. A, E. Red lines indicate mean. *P<0.05, **P<0.001, ****P<0.0001, ns non-significant; 
two tailed Mann-Whitney test. 
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by naïve B cells. To understand whether the recruited naïve B cells underwent class switching, 
IGHC regions were analyzed (Fig. 12D). Post third infection, frequency of less mutated 
antibodies with IGHG was increased compared to second infection. This was also observed by 
a drop in the mean SHM of Ig genes that carried the IGHG1 constant region (Fig. 12E). In 
conclusion, CHMI in malaria naïve donors recruited pre-existing memory B cells from other 
infections. However, over the course of three infections, naïve B cells were recruited with 
increased frequency in the majority of donors and showed signs of class-switching to IGHG1. 
 
4.8 Antibody R/S mutation ratio profile 
To understand whether the isolated B cells underwent antigen mediated selection, the ratios of 
replacement to silent mutations (R/S) in the different antibody regions were compared (Fig. 
13A). Increased frequency of replacement to silent mutations in the antibody complementarity 
determining regions (CDR) compared to its frame work regions (FWR) is reported to be a bono 
fide sign of antigen mediated selection95,96. As expected, the R/S ratios were higher in CDRs 
 
 
compared to FWRs, both in CSP memory B cell and plasmablast antibodies (Fig. 13B). The 
calculated ratios were comparable to published ratios from the resting memory B cells in 
Figure 13. Replacement (R) to silent (S) ratio of different antibody regions. A,B. R/S ratio of frame work 
(FWR) and complementarity determining regions (CDR) calculated for CSP memory B cell and plasmablast 
antibodies represented for individual donors (A) or all donors pooled (B). Error bars indicate standard error mean. 
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healthy adults. This indicates the clear CSP mediated selection of mutations in the CSP memory 
B cell antibodies. 
 
4.9 Degree of clonal expansion 
A strong indication for antigen-specific selection is the presence of clonally-related cells within 
the antigen-specific population99. In order to characterize the degree of focused response 
towards CSP, clonally expanded B cell clusters were identified as B cells with the same Ig 
heavy and light chain genes with shared or non-shared somatic hypermutations. The Ig gene 
sequences from all time points, both in the CSP memory and plasmablasts, were analyzed and 
clonally expanded clusters were defined. In 5/8 donors, the degree of clonal expansion in CSP 
memory B cells was continually increased in response to each infection, leading to a total of 
up to ~ 50% of all CSP memory B cells post third infection (Fig. 14 A,B). Comparatively, the 
relative clonal expansion in 3/8 donors were weaker and showed variations in CSP memory B 
cell response in humans. Interestingly, maintenance and re-recruitment of memory B cell 
clusters from one infection to another was observed (Fig. 14C). 
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To measure the diversity of the clonally expanded cells, the Shannon diversity index was 
calculated, with 0 and 1 being entirely polyclonal and monoclonal responses, respectively (Fig. 
14D). Among the 5 donors who showed strong clonal expansion, all except for donor T2_051 
Figure 14. Analysis of clonally expanded B cell clusters. A. Bar plots depicting clonally expanded B cell clusters 
post three Pf infections and challenge. Expanded clusters are marked in unique colors and non-expanded B cells 
shown in white. B,C. Frequency of clonally expanded B cells observed for the donors (B) and circo plots of three 
representative donors where the B cell clusters that are recruited during later infections are linked (C). D.  Shannon 
diversity index of the clusters measured at III. ND: non-determined. E. Clonal expansion in the overall data (top) 
or the subsampled data set (bottom) at III. Each dot indicates a given subsample, red line indicates the mean of at 
most 50 subsamples and blue line indicates the observed clonal expansion. F. Representative B cell clusters with 
members of memory B cell (red: CD27+CD38-) and plasmablast (blue: CD27+CD38+). 
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showed a higher diversity in recruiting and expanding B cells with diverse Ig genes. To account 
for the sample number variability between the donors, CSP memory B cells post third infection 
were sub-sampled (n=12) from each donor and clonal expansion was estimated (Fig 14E). The 
donors with higher overall clonal expansion still showed higher mean clonal expansion 
calculated from the 50 random sub-samples. Taken together, the donors showed a diverse 
degree of clonal expansion in CSP memory B cells with a strong response in 5/8 donors.   
Compared to CSP memory, clonal expansion in the plasmablast compartment was lower in all 
donors. In contrast to subunit vaccines, live Pf sporozoite infection provides the immune 
system with a diverse set of antigens (Fig. 14B,E). Because plasmablasts were not selected for 
a given antigen, the individual antigen specific clones would be diluted. Hence, the lower 
degree of clonal expansion in plasmablasts reflects the response against diverse Pf antigens. 
To check whether the B cell clusters identified in CSP memory compartments also shared a 
plasmablast phenotype, clonally expanded B cells were assessed for CD38 expression, an 
activation marker upregulated in plasmablasts (Fi. 14F). In several CSP binding B cell clusters, 
a part of the cluster members showed a memory B cell phenotype (CD27+CD38-), while the 
rest showed a plasmablast phenotype (CD27+CD38+). This evidence underlines the potential 
of a single ancestor B cell to take part in a germinal center reaction and potentially contribute 
to both memory B cell and plasmablast compartments. 
 
4.10 Ig gene repertoire analysis 
To identify an enrichment of molecular signatures, VH genes of CSP memory B cells were 
compared to those of plasmablasts (Fig. 15). Given that plasmablasts are presumably mounted 
against several antigens, they were used as internal controls to assess the specific nature of CSP 
memory B cell Ig genes., CSP memory B cells in 4/8 donors showed a higher enrichment of Ig 
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genes with gene segments of the VH3 family, compared to those of plasmablasts. Interestingly, 
these 4 donors showed strong clonal expansion by recruiting and expanding B cells with 
diverse Ig genes as identified in Fig. 14, post three infections. In these 4 donors, the enrichment 
in VH3 gene segments was driven mostly by either IGHV3-33 and/or IGHV3-23, and the gene 
segments were recorded in several of the clonally expanded B cell Ig genes. In contrast, donor 
T2_051 showed an enrichment of VH1 and VH4 family gene segments and the majority of this 
enrichment was due to strong clonal expansion of only two B cell clusters. While individual 
donors showed enrichment in a given family of segments, there was greater diversity in the 
light chains regarding the segments used amongst the donors, both in CSP memory B cells and 
in plasmablasts (Supplementary Fig. S3). 
 
Overall, the Ig heavy gene repertoire showed distinct gene signatures that were enriched in 
CSP memory B cells among the donors that showed strong clonal expansion. In the majority 
of the donors, this enrichment was due to the recruitment and expansion of several B cell 
clusters carrying these Ig genes. 
 
Figure 15. IGHV family 
usage. Heat map 
illustrating frequency of 
antibodies with different 
IGHV families in CSP 
memory B cells (left) 
and plasmablasts (right) 
in indicated donors. 
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4.11 CSP binding quality of memory B cells  
To characterize the antigen binding quality of the antibodies, Ig genes from 422 CSP memory 
B cells and clonally related plasmablasts, with special focus on clonally expanded cells, were 
cloned and expressed as recombinant monoclonal antibodies. To compare the antibodies for 
CSP binding, Enzyme Linked Immunosorbant Assay (ELISA) was performed using 
recombinantly expressed CSP at several dilutions of the monoclonal antibodies (Fig. 16A). 
Only 6% of the antibodies post first infection showed detectable CSP binding in ELISA, 
indicating that it was too early to generate high CSP binding antibodies after seven days post 
first infection (Fig. 16B). However, the frequency of CSP binding antibodies post second and 
third infection increased to 47% and 66%, respectively. This significant increase in CSP 
binding antibodies indicates the global affinity maturation towards CSP over the course of three 
Pf infections. 
 NANP repeat units are reported to be the immunodominant B cell epitope in CSP. To assess 
if the antibodies targeted the NANP repeat, ELISA was performed using NANP10 repeat units 
at several dilutions of the monoclonal antibodies (Fig. 16C). This assay confirmed that the 
majority of the CSP binding antibodies targeted the NANP repeat units. 
                         
 
 
Figure 16. Antibody reactivity assessment. A. Binding of memory B cell antibodies to CSP in ELISA detected 
by absorbance at indicated antibody concentration. 2A1087, 91 (red) and mGO5388 (blue) are used as positive and 
negative controls. B, C. Area under the curve values of antibodies binding to CSP (B) and NANP10 (C) post 
three Pf infections. Data is representative of two independent experiments. ***P<0.001, ****P<0.0001; two 
tailed Mann-Whitney test. 
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To summarize, at least two Pf infections were required to generate high CSP binding antibodies 
and the third infection increased the frequency of high CSP binding antibodies even further. 
The globally increased high CSP binding antibodies targeted NANP repeat units, the reported 
immunodominant B cell epitope. 
 
4.12 Poly-reactivity of CSP memory B cell antibodies 
To determine whether the antigen binding in CSP memory B cell antibodies is specific or poly-
reactive, antibodies were tested in ELISA for binding to three structurally different antigens: 
dsDNA, insulin and LPS (Fig. 17A). Antibodies that bound at least two of the three antigens 
were defined as poly-reactive. The assay showed that 30% of antibodies cloned from memory 
B cells post first infection showed poly-reactivity (Fig. 17B). However, in response to the 
second infection, the frequencies of poly-reactive antibodies were significantly decreased. To 
summarize, the poly-reactive features of the antibodies provided an added advantage in 
recruiting the B cells post first infection. The relative decrease in the frequency of poly-reactive 
antibodies post second and third infection indicates an efficient recruitment and selection of B 
cells with CSP specific antibodies. 
         
 
Figure 17. Antibody poly-reactivity 
assessment. A. Poly-reactive nature of 
antibodies assessed by binding to the indicated 
antigen at 1 µg/ml measured by absorbance at 
405nm. ED3889 (red) and mGO5388 (blue) are 
used as positive and negative controls. B. 
Frequency of poly-reactive antibodies detected 
at the three infection time points. Data is 
representative of two independent experiments. 
*P<0.05, 2 × 2 Fischer exact test. 
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4.13 In vitro functional characterization of CSP memory B cell antibodies 
To determine the functional capacity of the antibodies in inhibiting sporozoite traversal 
activity, the antibodies were assessed in an in vitro hepatocyte traversal assay91 (Fig. 18A). 
Comparable to CSP binding, antibodies from CSP memory B cells post first infection did not 
inhibit sporozoite traversal. However, the monoclonal antibodies from the later infection time 
points showed significantly increased sporozoite traversal inhibition compared to first 
infection. The Pf sporozoite traversal inhibition had a remarkable correlation with the CSP 
binding nature of the monoclonal antibodies (Fig. 18B). To summarize, over the course of three 
infections, high CSP binding antibodies that were enriched in CSP memory B cells showed 
remarkable functionality regarding their Pf sporozoite inhibitory capacity in an in vitro 
traversal assay. 
 
4.14 Kinetic parameters of CSP memory B cell antibodies 
                    
 
 
Figure 18. Antibody in vitro functional assessment. 
A,B. Pf sporozoites hepatocyte traversal inhibition of 
monoclonal antibodies measured in the in vitro 
traversal assay (A) and the inhibition compared to the 
antibody CSP binding indicated by ELISA AUCs (B). 
Red line indicates mean. 2A1087,91 (red) and mGO5388 
(blue) are used as positive and negative controls. Data 
is representative of two independent experiments. 
****P<0.0001, ns: non-significant; two tailed Mann-
Whitney test.  r indicates Spearman correlation 
coefficient. 
Figure 19. Antibody affinity and kinetic parameters assessment. A. Range of antibody affinity to NANP5 
measured by SPR (left) and comparison of antibody frequencies with the indicated affinity ranges between 
infection time points II and III (right). **P<0.01; Chi-square test. B, C. Kinetic on (B) and off rates (C) compared 
between antibodies from infection time points II and III. *P<0.05, ns: non-significant; two tailed Mann-Whitney 
test. 
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To characterize the binding affinity and deduce kinetic parameters of CSP binding antibodies, 
a NANP5 repeat unit was used as a minimal epitope in the Surface Plasmon Resonance (SPR). 
The affinity measurement showed the overall range of NANP affinity to be that of the reported 
range of antigen-antibody interactions: 10-5 to 10-10 M 100,101(Fig. 19A). It is important to note 
that the overall antibody affinity to CSP may be increased due to the repetitive presence of the 
minimal epitope in the full length protein. To qualitatively compare the affinity maturation, 
frequencies of antibodies with different affinity ranges were compared between the second and 
the third infection (Fig. 19A). Interestingly, antibodies post third infection showed a higher 
frequency in both the low affinity range (> 10-5 M) and the high affinity range (<10-8 M). To 
better understand the enrichment, the kinetic on and off rates of the antigen-antibody 
interaction were compared (Fig. 19B,C). While the kinetic on rates did not show any significant 
difference between the second and third infections, there was a significant reduction in the 
kinetic off rates explaining the enrichment of higher affinity antibodies in the third infection. 
In summary, the kinetic affinity of NANP targeting antibodies was in the reported range and 
the kinetic maturation of the antibodies between second and third infection occurred due to the 
significant reduction in the kinetic off rates of the interaction.    
 
4.15 Clonal evolution of CSP memory B cells 
To characterize the affinity maturation on single expanded B cell cluster level, clonally related 
antibodies that were diversified through SHM were grouped and their affinities were compared. 
Surprisingly, cluster members with different mutations showed a similar affinity in the majority 
of the clusters (Fig. 20A). Interestingly, memory B cells with a germline antibody configuration 
(0 mutations in heavy and light chain) isolated in some clusters already possessed an affinity 
that was comparable to its mutated counterparts. To check whether the germline binding also 
existed in the clusters, unmutated common ancestors (UCA) were made by reverting the 
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observed mutations back to the germline (Fig. 20B). In the analyzed clusters, the generated 
UCA showed similar affinity compared to the mutated variants, confirming the previous 
observation. While affinity maturation was indeed observed while the antibody affinity 
increased by 100 folds, this observation was found only in a few clusters and restricted to 
individual antibodies in the clusters (Fig. 20C). Affinities of clonally related antibodies that 
were isolated post different infections were also comparable to each other (Fig. 20D). To 
summarize, the global increase in CSP binding antibody quality was not observed in several of 
the diversified antibody clusters. In the majority of the clusters, the germline antibodies already 
possessed an affinity that was maintained in the mutated variants throughout the evolution of 
response.  
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4.16 SHM pattern of high CSP binding antibodies 
The observation that germline or less mutated antibodies in the cluster already had a high 
affinity prompted for the analysis of SHM patterns in antibodies that showed CSP binding. Fig. 
21A compares the total SHMs present in IGHV and IGKV/IGLV of the monoclonal antibodies 
to their  
 
binding to CSP defined by ELISA AUC. This plot showed that although there were mutated 
antibodies that exhibited CSP binding, the majority of the high CSP binding antibodies carried 
few mutations in the heavy and light chain genes. This plot also revealed that these high 
binding, less mutated antibodies were recruited even more often after second and third 
infections and performed better inhibition in the in vitro hepatocyte traversal assay (Fig. 21B). 
Interestingly, this observation was true for the antibodies cloned from day7 post challenge as 
Figure 20. Inefficient antibody affinity maturation in CSP response. A,B. Antibody affinities of diversified 
B cell clusters towards the minimal epitope NANP5 showing no appreciable difference amongst the clonal 
members (black circle) (A) and when compared to the germline version of the cluster (white circle) (B). C. B 
cell clusters with individual members showing >100 x affinity maturation. A-C. Sum mutations in the heavy and 
light chain are represented in x-axis. D. Affinity of cluster members compared across Pf infection time points I, 
II and III and the challenge C. Data is representative of at least two independent experiments. ns non-significant; 
two tailed Mann-Whitney test. 
Figure 21. SHM profile 
compared to antibody binding 
and functional characteristics. 
A,B. CSP binding of the 
antibodies indicated by ELISA 
AUC (A) and Pf sporozoites 
traversal inhibitory capacity of 
the antibodies (B) compared  to 
their sum mutations in the IGHV 
and IGKV/IGLV genes, post 
indicated infection time points. 
Red and green dots indicate the 
positive (2A10)87,91 and negative 
control (mGO53)88. Data is 
representative of at least two 
independent experiments. 
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well. To summarize, the majority of the high CSP binding antibodies generated in response to 
CHMI carried little to no SHMs, indicating that the role of germline residues in the antibodies 
lies in mediating CSP binding.  
 
4.17 Ig gene features of high CSP binding antibodies 
Given the observation that the high CSP binding was not mediated through SHM, Ig gene 
features such as Ig gene segments and CDR3 length were assessed to define CSP binding 
features.  Comparing CSP binding through ELISA of antibodies carrying Ig gene segments of 
different families showed the enrichment of high CSP binding in antibodies with segments of 
the VH3 gene family (Fig. 22A). Also, comparing the CDR3 amino acid (aa) length of the 
kappa chain showed the enrichment of high CSP binding in antibodies with a KCDR3 length 
of 8 aa (Fig. 22B). This significant enrichment was clearly visible while comparing the NANP5 
affinities of the antibodies with a KCDR3 length of 8 or 9 aa (Fig. 22C). The frequency of 
antibodies with NANP affinity <10-7 M was enriched in the antibodies with a KCDR3 length 
of 8 aa. To summarize, VH3 gene family usage and an 8 aa long KCDR3 enriched for high 
CSP binders as detected by CSP ELISA and SPR measurements for NANP5 repeat units. 
 
                            
 Figure 22. Ig genes features compared to antibody CSP binding. A, B. CSP binding indicated by ELISA 
AUC of the antibodies compared to their IGHV gene families (A) and KCDR3 amino acid length (B). C. NANP5 
affinities of the antibodies with 8 or 9 amino acid long KCDR3. Red lines indicate mean. ****P<0.0001; two 
tailed Mann-Whitney test. A,B. Data is representative of two independent experiments. 
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4.18 Ig heavy and light chain genes of high affine antibodies  
To identify the Ig gene segments that contribute to better NANP binding, antibodies with 
detectable NANP5 affinity by SPR were assessed for their gene segments in the heavy and 
kappa chain (Fig. 23). Based on the clear enrichment of high affinity antibodies (NANP5 KD < 
10-7 M) in those that carried an 8 aa long KCDR3, CSP binding antibodies were sorted for high 
and low NANP binding (NANP5 KD < 10-7 M and NANP5 KD > 10-7 M, respectively) and for 
having an 8 or 9 aa long KCDR3. Association of the heavy and light chain V gene of these 
groups identified IGHV3-33 and IGKV1-5 / 3-11 / 3-20 with 8 aa KCDR3 as the gene 
configurations of the high affine antibodies. Antibodies with these gene features were isolated 
from 4 donors who showed strong clonal expansion in CSP memory B cells, indicating the 
prevalence of high quality antibodies in malaria naïve donors. Furthermore, antibodies with the 
mentioned gene segments and a 9 aa CDR3 length did not exhibit high affinities (NANP5 KD< 
10-7 M), highlighting the restriction placed by the KCDR3 length.  
 
 
Figure 23. V gene repertoire of 
CSP binding antibodies. 
Frequencies of VH-Vk gene 
association of antibodies with 
KCDR3 amino acid length of 8 
(left) and 9 (right), and with NANP5 
affinity KD < 10-7 M (top) or KD > 
10-7 M (bottom). Donors with the 
observed gene associations are 
listed. 
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4.19 Comparison of donors based on high CSP binding Ig gene features 
VH3 gene segment usage and an 8 aa long KCDR3 in CSP memory B cells enriched for high 
CSP binding. Besides, the degree of clonal expansion served as an indicator of focused B cell 
response over three Pf infections. Considering these three features as signs of a qualitative CSP 
response, Ig sequences of CSP memory B cells were analyzed to estimate the frequency of 
VH3 family genes, 8 aa long KCDR3 and mean clonal expansion post three infections from 
the multiple subsampled data set. Principal Component Analysis (PCA) performed on the 
above three Ig gene parameters to compare the donors clustered the donors, T2_071, T2_072 
and T2_073 into one group and T2_017, T2_026 and T2_035 into another. Donor T2_042 was 
present in-between these groups, whereas donor T2_051 was separated from the rest (Fig. 
24A). 
                     
 
 
Interestingly, the distinct pattern of clustering was also reflected in the mean CSP AUC of the 
monoclonal antibodies cloned from these donors (Fig. 24B). Donors T2_071, T2_072 and 
T2_073 had a higher frequency of high CSP binders, whereas T2_017, T2_026 and T2_035 
had very few, if any, high CSP binders. The quality of the antibodies from donor T2_042 was 
in-between the high and weak responders. While the degree of clonal expansion in T2_042 was 
Figure 24. Inter-donor variability in CSP response. A. Principal component analysis of the donors based on, 
VH3 family frequency and antibodies with 8 amino acids long KCDR3 frequency in overall CSP memory B 
cells, mean clonal expansion of the subsampled data set from CSP memory B cells post third Pf infection (Figure. 
12D). Individual donors are indicated in different colors. B. CSP binding of antibodies cloned from the 8 donors 
indicated by ELISA AUCs. Red lines indicate mean. B. Data is representative of two independent experiments. 
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comparable to the high responders, the frequency of high CSP binders was low. It is 
noteworthy, that the high binders in these donors were the ones that carried fewer mutations. 
Donor T2_051 was distinct in the expansion of clones with high CSP binding gene features 
and hence had no high CSP binding antibodies. To summarize, high CSP binding Ig gene 
features enabled distinguishing donors with high and low quality CSP response. 
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5. Discussion 
5.1 High throughput Ig gene amplification strategy 
The high throughput platform reported here for the amplification of full length Ig genes on 
single cell level provides a significant improvement on the existing strategies. The limitations 
of the bulk sequencing strategies which lose Ig heavy and light chain gene pairing102-104 and 
the other single cell approaches105 which do not provide full length Ig gene information are 
overcome here85. The throughput offered by the barcoded primer matrix in combination with 
the NGS bulk sequencing results in the efficient generation of Ig gene sequence information of 
several thousand cells at a much reduced cost and time92. The power of this strategy relies in 
deep sampling rare populations, identifying clonally expanded cells, understanding gene 
signatures and enabling Ig gene cloning and characterization of monoclonal antibodies. The 
application of the strategy is further exemplified in this thesis in following the onset and 
longitudinal evolution of CSP reactive memory B cells to understand how the selection of B 
cells with high affine antibodies develops in CHMI. Additionally, random hexamers used in 
cDNA library synthesis leaves room for further development of tools to analyze the 
transcriptome on the single cell level and characterizing the cell types.   
 
5.2 Recruitment of pre-existing memory B cells in CSP response 
Highly mutated memory B cells were recruited throughout the course of the three infections, 
although the overall mean mutation count decreased due to increased recruitment of naïve B 
cells95-97. While the antibodies from some mutated memory B cells show CSP binding, the 
majority of them carry antibodies with affinity below the ELISA detection threshold. The 
higher prevalence of poly-reactive cells within this population may partly explain this 
observation96,106. Further, due to the lower threshold needed for activation107-109, pre-existing 
memory B cells from non-Pf infections were re-recruited in to the Pf response. Studies using 
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mouse model report the BCR extrinsic and intrinsic stimulation of memory B cells110. 
Transcriptional and epigenetic changes during memory B cell differentiation prepare the cells 
to be more responsive111. This provides the explanation for the high recruitment of mutated 
memory B cells during primary Pf infection presumably through BCR extrinsic mechanisms. 
Nonetheless, naïve B cells carrying high affine antibodies selected during the second and third 
infection out-compete the less affine B cells. The efficient clonal selection based on BCR 
intrinsic stimulation results in the generation of high quality antibodies preferentially in the 
clonally expanded B cells40.  
Interestingly, some CSP binding antibodies at later infections carried relatively high Ig gene 
mutations (SHM count > 20), indicating the corresponding memory B cells were less likely to 
have been recruited as naïve B cells95-97. Although their affinity was not as high as the naive B 
cell antibodies, they still exhibited significant Pf spz inhibition. The most likely explanation is 
that these are memory B cells from non-Pf response, but were nevertheless recruited during Pf 
infection due to their cross-binding to CSP. Although NANP repeat units are exclusively 
present only in CSP, it is possible that the antibodies from the pre-existing memory B cells 
recognize a structurally similar epitope. This notion is supported by a recent study that reported 
the memory B cells generated in response to DENV1 infection to actively take part during 
ZIKA infection due to the structural overlap of the envelope domain present in both viruses112.  
 
5.3 Coexistence of B cells with high and low affine antibodies 
While the average antibody affinity improved during three Pf infections, B cells with high and 
low affine antibodies were maintained throughout. This could be the result of minimum affinity 
required to reach the threshold BCR signaling and hence positive selection. For monovalent 
antigens, the reported minimum antigen-antibody affinity required for antigen uptake and 
presentation for TFH help is 10-6 M 100. However, for antigens with repetitive epitopes like CSP, 
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this minimum threshold could be lowered and allows for permissive selection of low affine 
antibodies, as suggested by the anti-CSP antibodies with ~10-5 M affinity. Although the overall 
CSP response was initiated by the low affine antibodies, over the course of three infections, 
GC competition selects for B cells with high affine antibodies (~10-7 M), and such B cells are 
enriched. A recent study using multi-photon microscopy of GCs suggested that although the 
average affinity of GC B cell antibodies increases, homogenizing selection takes place to a 
lesser extent99. The study reported the presence of B cell clones with diverse affinities selected 
in several GCs, ensuring parallel affinity maturation. Although this study focused on GC B 
cells, the CSP memory B cells generated during CHMI show a similar picture. Maintenance of 
B cells with a broad range of antibody affinities in the memory B cell pool rescues the system 
from narrowing the response to a few high affinity clones. Such diverse affinity clones could 
be re-recruited in a future response and still undergo affinity maturation. While the impact of 
antibody clones targeting different epitopes has been studied by following the evolution of 
gp140 antibody responses in HIV infection113, the implication of antibodies with a broader 
affinity ranges for functional vs non-functional immune responses remains to be studied. 
 
5.4 High affine CSP antibodies are germline encoded 
CHMI with high sporozoite dosages may have provided an ideal environment for the selection 
of antibodies with desired gene features (IGHV3-33 + IGKV1-5) and high affinity from the 
extensively diverse naïve B cell pool. Other studies also present the enrichment of gene 
signatures in several responses such as IGHV3-23 + IGKV1-5 in DENV1 and ZIKV envelope 
domain binding antibodies112, IGHV3-30 in antibodies against Pneumovax®23 cell wall 
polysaccharide114 and IGHV1-2 and IGHV1-69 in HIV gp140 binding antibodies115,116. It is 
important to note that these responses generated mutated antibodies with the indicated gene 
signatures112,117,118. The CSP response in CHMI remains unique in generating high affine 
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germline antibodies with the mentioned gene features in humans. Mouse immunization studies 
with the protein antigens Bacillus anthracis protective antigen and influenza hemagglutinin 
reported the recruitment of GC B cells with near germline antibodies and prominent gene 
signatures119.  A mechanistic explanation for the dominance of clonal selection of B cells with 
high affine germline antibodies over generating them through SHM comes from the 
mathematical modeling with an immunization scheme similar to CHMI (Buchauer and Hoefer, 
unpublished results). The model predicted that the higher the complexity of an antigen, 
requiring more mutations by the antibody to increase affinity, the lesser the likelihood of intra-
clonal affinity maturation. Much like the experimental observation in CHMI, B cells with high 
affine antibodies were predominantly selected from the naïve B cell pool, the effect 
compounded by the high antigen dose and increased GC life time. In this respect, the evolution 
of the CSP response in CHMI offers significant insight in the onset and development of 
antibody response against complex protein antigens in humans. 
 
5.5 Role of IgM memory B cells in CSP response 
Predominant usage of IgM isotype in CSP response would indicate the origin of the B cells in 
the naïve B cell compartment or in IgM memory B cells. Intravenous (i.v) immunization should 
target antigens to the spleen. Therefore i.v injection of sporozoites should induce strong 
immune response in the spleen120, a residential place of IgM memory B cells121,122. The overall 
dominance of VH3 gene family antibodies is reported in the splenic IgM memory B cells122, a 
feature shared by high CSP binding antibodies. However, individual members of the expanded 
IgM memory B cell clusters showed isotype class-switching to IgG, indicating the plasticity of 
IgM memory B cells. Further, high R/S ratios in CDRs compared to FWRs in CSP-memory B 
cells from all donors, suggesting that the antibodies had developed in bona fide GC 
responses95,96 and not from extra-follicular responses and that there was no major effect of 
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chloroquine on GC reactions. Studies following IgM memory cells report that in response to 
secondary antigen exposure, IgM memory B cells are more likely to be recruited in the germinal 
center48,123 while IgG memory B cells are more likely to differentiate into antibody secreting 
plasmablasts111,124,125. This however does not exclude IgM memory B cells from differentiating 
into plasmablasts or IgG memory B cells being recruited into secondary germinal centers. 
Perhaps this explains the serum IgM and IgG antibodies seen post second and third Pf 
infections. Additionally, serum IgM antibodies, secreted either as pentamers or hexamers, offer 
enhanced binding through avidity even when the individual paratope-epitope interaction is of 
less affinity. Although this provides no evidence for selection of IgM isotype in CSP memory 
B cells, multimeric binding of IgM antibodies might be more suited for NANP targeting 
antibodies, due to the repetitive nature of the NANP epitope in CSP and the protein on the 
parasite surface.  Given that the IgM memory B cell antibodies were recombinantly expressed 
as IgG in this study, the overall avidity and potency of these antibodies could be 
underestimated. A recent study showed that the IgM memory B cell antibodies against CSP 
isolated from semi-immune African adults offered significant protection in in vitro and in vivo 
infection models91. A functional role of IgM antibodies in malaria has been reported in murine 
models in controlling the asexual stage of erythrocytic parasites126. These studies, along with 
the one presented in this thesis, shed light on the previously underappreciated role of IgM 
memory B cells in malaria. 
 
5.6 Inter-donor variability in anti-CSP antibody response 
The variability seen in the degree of clonal expansion was also reflected in the CSP binding 
quality of the memory B cell antibodies in the majority of the donors, as CSP binding antibodies 
are more frequently found in the clonally expanded B cells than in the non-expanded B cells. 
It is important to note that, although CSP is predominantly expressed on the sporozoite surface, 
Discussion 
 66  
 
sporozoite infection may also present other Pf antigens to the immune system127. Analysis of 
serum antibodies in the Pf antigen proteome array detected binding to several antigens in the 9 
donors93. Based on the degree of expansion and repertoire usage, the plasmablast response 
showed no significant difference among the 9 donors, indicating that random cloning and 
characterizing of plasmablasts would identify the antigens targeted in a donor. The fact that all 
the donors were protected during the challenge infection indicates that protection may not be 
mediated only through the anti-CSP antibodies. Studies on irradiated sporozoite immunization 
in non-human primates report the protective capacity of liver resident CD8 T cells128. This 
shows the diverse ways in which protection can be established. The repertoire diversity of B 
cells and T cells amongst donors might initiate and lead the response in different directions, 
particularly in successive infections. 
 
5.7 Generation of high affine CSP antibodies 
In comparison to natural infections, control of blood parasitemeia using chloroquine 
chemoprophylaxis in CHMI might have focused the immune response towards sporozoites 
antigens. This is supported by a recent report where mice infected with parasites that did not 
differentiate from sporozoites to merozoites, either through genomic mutations or 
chemoprophylaxis, showed stronger response against sporozoites antigens compared to mice 
infected with wildtype sporozoites129. Given that the recruitment of high affine antibodies 
occurred in three donors after 2 Pf infections (T2_071, 072 and 073) and in one donor after 
challenge infection (T2_042), their generation may depend on the precursor B cell frequency 
in the highly diverse naïve B cell pool. The dynamic changes of the antibody repertoire within 
naïve B cell population in healthy adults and how it changes during inflammatory conditions 
is not known. A potential vaccine would need to maximize the change of eliciting a functional 
antibody response in every donor even if there are changes in the antibody repertoire. The 
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recently developed HIV gp140 CD4 binding site epitope based on germline targeting 
immunogen (eOD-GT8) predicted the precursor B cell frequency in naïve B cell population to 
be 0.0056% in HIV uninfected donors130. Little is known about the precursor B cell frequencies 
of other vaccine antigens. Similar studies estimating the precursor B cell frequencies binding 
to NANP repeat units would provide significant insight in vaccine design and in establishing 
dose and time frame of immunizations. 
 
 
Outlook 
 68  
 
6. Outlook 
Passive immunization with CSP binding antibodies in in vivo animal models shows protection 
against the infection. The CSP binding antibodies reported in this thesis could be used as a 
preventive measure for travelers by passive vaccination. NANP affinity measurements indicate 
the strong potential of the antibodies in offering in vivo protection. A murine antibody targeting 
the N-terminal domain of CSP (5D5) showed better in vivo protection than NANP binding 
antibody (2A10)131, indicating the presence of additional functional epitopes in CSP. Thus, 
binding to those non-NANP epitopes should be assessed. To identify the most potent antibody, 
a panel of high affine antibodies targeting different CSP epitopes should be titrated and 
assessed for their inhibitory capacity while infecting humanized mice by Pf or C57BL/6 mice 
by P. berghei expressing PfCSP.   
One of the major goals in the field is to develop a vaccine candidate that offers sterile immunity 
and long-term protection. The leading CSP based vaccine candidate RTS,S offers protection 
with only with a low efficacy and the protection waned rapidly67. The study presented here 
identified germline high affine antibodies that were elicited in CHMI. Understanding their 
mode of epitope binding through antigen-antibody co-crystals would allow the identification 
of protective epitopes for CSP based immunogen designs. Using the immunogens, the 
frequency of precursor naïve B cells with high CSP affine antibodies in malaria naïve donors 
can be estimated. Further, the minimum dose, duration and booster vaccination scheme should 
be designed and tested to recruit the precursor B cells in all donors. In the end, the finding 
should also be corroborated in the target population, such as the African infants and pre-
exposed semi immune adults.  
The study presented here focused on memory B cells, but the serum antibody titers that offer 
sporozoites inhibition come from plasmablasts and plasma cells. Blocking of sporozoites 
during the transitory period they spend in blood before liver infection could be only achieved 
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by ensuring high antibody titers. It is also crucial to maintain stable high titers during the time 
of infection. While this can be achieved through passive immunization, a functional vaccine 
response determined by the immunogen design and adjuvant choice should aim at not only 
inducing high quality antibodies but maintaining the titers through long lived plasma cells.  
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8. Supplementary Material 
8.1 Antibodies 
ELISA capture antibody  
Goat anti-human IgG, Fcγ Jackson, ImmunoResearch Laboratories, West Grove, PA, USA 
  
ELISA secondary antibodies  
Goat anti-human IgG, Fcγ (HRP conjugated) Jackson, ImmunoResearch Laboratories, West Grove, PA, USA 
Goat anti-human IgM, Fc5µ (HRP conjugated) Jackson, ImmunoResearch Laboratories, West Grove, PA, USA 
Goat anti-human IgA, α Chain (HRP conjugated) Jackson, ImmunoResearch Laboratories, West Grove, PA, USA 
  
ELISA standard and control antibodies  
2A10 (chimeric antibody) 87,91 
ED38 (highly poly-reactive antibody) 89 
Human IgG1, kappa Sigma Aldrich Chemie GmbH, Steinheim, Germany 
mGO53 (non-poly-reactive antibody) 88 
  
FACS analysis antibodies & reagents  
7-AAD Invitrogen GmbH, Karlsruhe, Germany 
Mouse anti-human CD19 (BV786-conjugated) BD Biosciences GmbH, Heidelberg, Germany 
Mouse anti‐human CD21 (PE-Cy7conjugated) BioLegend GmbH, Fell, Germany 
Mouse anti-human CD27 (PE-conjugated) BD Biosciences GmbH, Heidelberg, Germany 
Mouse anti-human IgG (BV510-conjugated) BD Biosciences GmbH, Heidelberg, Germany 
Mouse anti-human CD20 (APC-H7-conjugated) BD Biosciences GmbH, Heidelberg, Germany 
Mouse anti-human CD38 (FITC-conjugated) BD Biosciences GmbH, Heidelberg, Germany 
Mouse anti-human CD138 (BV421-conjugated) BD Biosciences GmbH, Heidelberg, Germany 
  
 
8.2 Antigens 
CSP Kind gift of Dr. Kim Lee Sim, Protein Potential LLC, Rockville, 
MD, USA 
Δ-NCSP Kind gift of Dr. Silvia Boscardin, Department of Parasitology, 
University of São Paulo, Brazil 199 
DNA sodium salt from salmon testes Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Human recombinant insulin  Sigma Aldrich Chemie GmbH, Steinheim, Germany 
LPS, E.coli 055:B5  Sigma Aldrich Chemie GmbH, Steinheim, Germany 
NANP5, NANP10 Alpha Diagnostic Intl. Inc., Texas, USA 
 
8.3 Bacteria 
E.coli DH10B  Clonetech Inc., Palo Alto, CA, USA 
 
8.4 Bacterial culture media 
LB agar  (35 g/l) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Lysogeny broth (LB) (25 g/l) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Terrific broth (TB) Life Technologies GmbH, Karlsruhe, Germany 
8.5 Buffers, solutions and chemicals 
5x loading buffer gel electrophoresis 60 % (w/v) sucrose 
1 mM cresol red 
50x TAE buffer 2 M Tris  
0.05 % (v/v) Tween®20 
1 mM EDTA 
ABTS self-made buffer 0.1 M citric acid 
0.2 M disodium phosphate 
1 ABTS tablet/91 ml ABTS buffer 
ABTS tablets Roche Diagnostics GmbH, Mannheim, Germany 
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Acetic acid (CH3COOH) Sigma Aldrich Chemie GmbH, Steinheim,  Germany 
Ammonium chloride (NH4Cl2) Sigma Aldrich Chemie GmbH, Steinheim,  Germany 
Ammonium sulfate ((NH4)2SO4) Sigma Aldrich Chemie GmbH, Steinheim,  Germany 
Bovine serum albumin fraction V (BSA) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Calcium chloride (CaCl2) Sigma Aldrich Chemie GmbH, Steinheim,  Germany 
Citric acid (C6H8O7) (≥ 99.5 %) Sigma Aldrich Chemie GmbH, Steinheim,  Germany 
Coomassie Brilliant Blue G-250 BioRad Laboratories GmbH, München, Germany  
Coomassie Destaining Buffer 100 ml methanol 
400 ml acetic acid 
500 ml deionized water 
Coomassie Incubation Buffer  
 
50% (v/v) methanol 
2% (v/v) phosphoric acid 
17% (m/v) ammonium sulfate 
ad 1000 ml deionized water 
Coomassie Staining Buffer 0.66 g Coomassie Brilliant Blue G‐250/1l  
ad 1l Coomassie Incubation buffer 
Criterion™ TGX™ Precast Gels Bio-Rad Laboratories GmbH, München, Germany 
Cytochalasin D Sigma Aldrich Chemie GmbH, Steinheim,  Germany 
Dextran-rhodamine Thermo Fisher Scientific Inc., Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Disodium phosphate (Na2HPO4) Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Disodium phosphate (Na2HPO4) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
ELISA blocking buffer (concentration ELISA) 1x PBS 
0.05% (v/v) Tween®20 
1 mM EDTA 
ELISA blocking buffer 2 (antigen ELISA) 1% BSA/PBS 
ELISA blocking buffer 3 (serum ELISA) 1x PBS 
0.05% (v/v) Tween®20 
4% BSA 
Elution buffer pH 3 (antibody purification) 0.1 M glycine pH 3.0 
Ethanol Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Ethidium bromide (C21H20BrN3) Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
GIBCO™ 10x PBS (pH 7.4) Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ 1x PBS (pH 7.4) Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ Trypan Blue Stain 0.4% Life Technologies GmbH, Karlsruhe, Germany 
Giemsa’s stain improved R66 solution Gurr® VWR International, Leicestershire, UK 
Glycerol (C3H8O3) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Glycine (C2H5NO2)  Sigma Aldrich Chemie GmbH, Steinheim, Germany 
H2O2 Th. Geyer GmbH & Co. KG, Renningen, Germany 
Neutralization buffer pH 9.0 (antibody purification) 1M Tris 
Paraformaldehyde (PFA) Alfa Aesar, Thermo Fisher (Kandel) GmbH, Karlsruhe, Germany 
Percoll® GE Healthcare Life Sciences, Freiburg, Germany 
Polyethyleneimine (PEI) Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Protein G Sepharose™ Fast Flow GE Healthcare Life Sciences, Freiburg, Germany 
Rat collagen Sigma Aldrich Chemie GmbH, Steinheim, Germany 
SeaKem® LE Agarose Cambrex Inc., Rockland, ME, USA 
Sodium chloride (NaCl) Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Triton X-100 Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Trizma® base (C4H11NO3) Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Tween® 20 (C58H114O26) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
8.6 Cell lines 
U-266 DSMZ (ACC 9) 
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HC-04 BEI Resources, NIAID, NIH, Manassas, VA, USA: HC-04, 
Hepatocyte (human), MRA-975, contributed by Jetsumon 
Sattabongkot Prachumsri 
FreeStyle™ 293-F Thermo Fisher Scientific Inc., Darmstadt, Germany 
 
8.7 Cell culture media 
Ampicillin Sigma Aldrich Chemie GmbH, Steinheim, Germany 
GIBCO™ DMEM Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ HEPES Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ L-glutamine Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ MEM Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ PenStrep Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ RPMI Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ RPMI with L-glutamine Life Technologies GmbH, Karlsruhe, Germany 
GIBCO™ Trypsin EDTA 1x Life Technologies GmbH, Karlsruhe, Germany 
Human serum Haema, Berlin 
FreeStyle293 Expression media Thermo Fisher Scientific Inc., Darmstadt, Germany 
EX-CELL® 293 Serum-Free Medium Thermo Fisher Scientific Inc., Darmstadt, Germany 
 
 
8.8 Experimental parasites 
Pf NF54 Kind gift of Dr. Robert Sauerwein, Radboud University Medical 
Centre, NL 
 
8.9 Commercial kits 
AlexaFluor® 647 Antibody Labeling Kit Thermo Fisher Scientific Inc., Darmstadt, Germany 
NucleoBond® Xtra Midi / Maxi Macherey-Nagel GmbH & Co. KG, Düren, Germany 
NucleoSpin® 96 PCR Clean-Up Macherey-Nagel GmbH & Co. KG, Düren, Germany 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel GmbH & Co. KG, Düren, Germany 
NucleoSpin® Plasmid Kit Macherey-Nagel GmbH & Co. KG, Düren, Germany 
 
8.10 Enzymes and additives 
Cloning  
AgeI, BsiWI, SalI, XhoI New England Biolabs GmbH, Frankfurt am Main, Germany 
Buffer 1 10x New England Biolabs GmbH, Frankfurt am Main, Germany 
Cutsmart buffer 10x New England Biolabs GmbH, Frankfurt am Main, Germany 
T4 DNA Ligase New England Biolabs GmbH, Frankfurt am Main, Germany 
T4 DNA Ligase buffer 10x New England Biolabs GmbH, Frankfurt am Main, Germany 
  
RT and PCRs  
10x PCR buffer Quiagen AG, Hilden, Germany 
5x First strand buffer (RT) Life Technologies GmbH, Karlsruhe, Germany 
DTT Life Technologies GmbH, Karlsruhe, Germany 
Hotstart Taq DNA polymerase Quiagen GmbH, Hilden, Germany 
NP-40 Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Nuclease free water Eppendorf AG, Hamburg, Germany 
RNAsin® Promega Inc., Madison, WI, USA 
RT buffer Life Technologies GmbH, Karlsruhe, Germany 
SuperScript™ III Reverse Transcriptase Life Technologies GmbH, Karlsruhe, Germany 
Taq DNA polymerase Self-made 
 
8.11 Expression vectors 
Vectors (with γ1-, κ- and λ-chain C regions) Kind gift of Dr. J. Ravetch, Rockefeller University, New 
York City, USA 
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8.12 Nucleotides and nucleic acids 
1kb Plus DNA marker New England Biolabs GmbH, Frankfurt am Main, Germany 
Desoxynucleotide Triphosphates (dNTPs) Life Technologies GmbH, Karlsruhe, Germany 
Oligonucleotides MWG Biotech AG, Ebersberg, Germany 
Random Hexamer Primers Roche Diagnostics GmbH, Mannheim, Germany 
 
8.13 Instruments and consumables 
1.5 ml reaction tubes Sarstedt AG, Nümbrecht, Germany 
2 ml reaction tubes Sarstedt AG, Nümbrecht, Germany 
13 ml tubes   Sarstedt AG, Nümbrecht, Germany 
96-well Multiply®-PCR plate Sarstedt AG, Nümbrecht, Germany 
96-well skirted twintech PCR plate Eppendorf AG, Hamburg, Germany 
Alpha Imager™ 1220 Alpha Innotech Corporation Inc., San Leandro, CA, USA 
Aluminum foil seal 4titude, Surrey, UK 
AxioObserver Z1 fluorescence microscope ZEISS Microscopy, Oberkochen, Germany 
BD Aria II™ BD Biosciences GmbH, Heidelberg, Germany 
BD LSR II™  BD Biosciences GmbH, Heidelberg, Germany 
BD Microlance™ 3 30G x 1/2” BD Biosciences GmbH, Heidelberg, Germany 
BioPhotometer Eppendorf AG, Hamburg, Germany 
Bio-Spin® chromatography columns Bio-Rad Inc., Hercules, CA, USA 
Cell culture 48-well plate TPP, Trasadingen, Switzerland 
Cell culture 96-well plate  TPP, Trasadingen, Switzerland 
Cell culture 96-well plate (transparent bottom) TPP, Trasadingen, Switzerland 
Cell culture dish (150 mm)  BD Biosciences GmbH, Heidelberg, Germany 
CellStar sterile serological pipettes 2 ml, 5 ml, 10 ml, 25 ml, 
50 ml 
Greiner Bio-One GmbH, Frickenhausen, Germany 
Centrifuge 5180R (rotor A-4-81) Eppendorf AG, Hamburg, Germany 
Centrifuge 5417R (rotor F-45-30-11) Eppendorf AG, Hamburg, Germany 
CO2 Incubator CB210 Binder GmbH, Tüttlingen, Germany 
Cover slips Menzel-Gläser GmbH, Braunschweig, Germany 
CryoTube™ Vials Thermo Fisher Scientific Inc., Darmstadt, Germany 
Domed 12-cap strips (PCR tube strips) Bio-Rad Laboratories GmbH, München, Germany 
Electrophoresis chamber D3 (horizontal) Thermo Scientific Inc., Rochester, NY, USA 
ELISA plates (96-well, flat bottom) Costar Inc., Corning, Action, MA, USA 
FluoNunc Plates Costar Inc., Corning, Action, MA, USA 
FrameStar® 384 4titude, Surrey, UK 
Heraeus B5042 (Bacteria incubator) Kendro Laboratory Products, Weaverville, NC, USA 
Inoculating loops/needles, polystyrene VWR International Inc., Brigdgeport, NJ, USA 
Leica DM2000 LED Leica Microsystems GmbH Wetzlar, Germany 
M1000Pro plate reader  Tecan, Crailsheim, Germany 
Mastercycler® ep Gradient S Eppendorf AG, Hamburg, Germany 
Mastercycler® Pro 384 Eppendorf AG, Hamburg, Germany 
MiniVE vertical electrophoresis unit Höfer Inc., Holliston, MA USA 
Multichannel Pipet-Lite® LTS 2-20 μl, 20-200 μl, 100-1200 
μl 
Rainin Instrument Inc. LLC, Woburn, MA, USA 
Multipette plus Eppendorf AG, Hamburg, Germany 
Multitron Pro (Bacteria shaker) Infors HT, Bottmingen, CH 
Nanodrop™ 1000 Thermo Scientific Inc., Wilmington, DE, USA 
Neubauer Counting Chamber by Marienfeld Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Omnican® 50 Insulin Syringes, 12 mm 30 G B. Braun Medical Ltd, Sheffield, UK 
PC LG Electronics Deutschland GmbH, Ratingen, Germany 
Petri dishes (100 mm) Greiner Bio‐One GmbH, Frickenhausen, Germany 
Pipetboy acc Integra Biosciences GmbH, Fernwald, Germany 
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Pipet-Lite® LTS 0.1-2 μl, 2-20 μl, 20-200 μl, 100-1000 μl Rainin Instrument Inc. LLC, Woburn, MA, USA 
Polypropylene tubes (15 ml, 50 ml) Sarstedt AG, Nümbrecht, Germany 
Polystyrene round bottom tube (5 ml) with cell strainer cap  BD Biosciences GmbH, Heidelberg, Germany 
Slide-A-Lyzer® Mini Dialysis Devices Thermo Scientific, Rockford, IL, USA 
S-Monovette® EDTA K Sarstedt, Nümbrecht, Germany 
SpectraMax 190 Microplate Reader Molecular Devices Inc., Sunnyvale, CA, USA 
Stemi 2000 Stereomicroscope ZEISS Microscopy, Oberkochen, Germany 
Stuart® Gyro rocker SSL3 Sigma Aldrich Chemie GmbH Steinheim, Germany 
T75 cm2 flask BD Biosciences GmbH, Heidelberg, Germany 
Thermomixer comfort Eppendorf AG, Hamburg, Germany 
Vortex genie 2 Scientific Industries Inc., Bohemia, NY, USA 
Water bath with thermostat JULABO Labortechnik GmbH, Seelbach,  Germany 
Wax seal 4titude, Surrey, UK 
8.14 Software 
FlowJo v10.0 Treestar Systems Inc., Ashland, USA 
GraphPad Prism 6.07 GraphPad Software Inc., La Jolla, USA 
Illustrator® CS5 Adobe Inc., San Jose, CA, USA 
Mendeley Desktop Mendeley Ltd, London, UK 
Microsoft® Office 2011 Microsoft GmbH, Stuttgart, Germany 
Pearl Version 12.5, open source distribution 
PhotoShop® CS5 Adobe Inc., San Jose, CA, USA 
Rstudio version 0.99.484 RStudio, Inc., Boston, MA USA 
SoftMax Pro Molecular Devices, Sunnyvale, CA, USA 
 
8.15 Web Resources 
Clustal Omega http://www.ebi.ac.uk/Tools/msa/clustalo/ 
Ensemble Genome Browser http://www.ensembl.org/index.html 
Expasy SIB Bioinformatics Resource Portal http://expasy.org/ 
IMGT® http://www.imgt.org/ 
NCBI Ig Blast http://www.ncbi.nlm.nih.gov/igblast/ 
PlasmoDB http://plasmodb.org/plasmo/ 
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 9. Supplementary Figures 
                                                                                     
 
 
Supplementary Figure 1: Human expression vector maps. Human Igγ1, Igκ and Igλ expression vectors with 
the human Igγ1, Igκ and Igλ constant regions where corresponding Ig genes can be cloned in the multiple cloning 
site. The restriction sites used for cloning in a given vector are indicated. Upstream to the multiple cloning site, a 
murine leader sequence is located. Human cytomegalovirus (hCMV) promotor is used for expression. Ampicillin 
resistance allows for the screening of the vectors. Figure is adapted from Tiller (Tiller, T. The frequency of Self-
Reactive Human and Mouse IgG+ B Lineage Cells in Health and Autoimmunity (Humboldt Universität zu Berlin, 
2009)). 
 
 
 
Supplementary Figure 3. Vk and Vl family usage. A,B. Frequency of Vk (A) and Vl (B) gene family usage in 
CSP memory B cells antibodies compared to that of plasmablasts in individual donors represented as a heatmap.
Supplementary Figure 2. Ig 
gene sequence analysis. A, B. 
Frequencies of IGHV, IGKV and 
IGLV gene families (A) and 
isotype subclass (B) in the healthy 
donors HD1-3.  C. SHM count 
per V gene of IGHV, IGKV and 
IGLV genes. This figure is 
adapted from85. 
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10. Supplementary Tables 
Table S1. Number of CSP memory B cell antibodies sequenced and cloned 
 after infection I, II and III  
   
CSP memory 
  Antibody sequences* Antibodies cloned 
donors I II III I II III 
T2_017 29 9 12 10 6 12 
T2_026 17 13 31 4 3 9 
T2_035 58 18 32 8 4 10 
T2_042 2 12 52 1 8 29 
T2_051 29 62 90 15 22 28 
T2_052 5 6 1 0 0 0 
T2_071 1 22 124 1 16 33 
T2_072 17 53 95 7 23 37 
T2_073 NA 86 142 NA 29 51 
   
   
Table S2. Number of plasmablast antibodies sequenced after infection I, 
II and III 
   
Plasmablast  
  Sequences*  
donors I II III  
T2_017 58 64 38  
T2_026 73 229 241  
T2_035 181 316 250  
T2_042 38 123 103  
T2_051 165 211 262  
T2_052 246 226 23  
T2_071 72 283 217  
T2_072 137 109 191  
T2_073 NA 209 147  
   
*paired functional IGH and IGK/IGL genes  
NA: Not available  
 
Supplementary Table 3: Primer Sequences84,85. 
 
1st heavy PCR: 
Forward primer 
hIGHV-1/7-066-fw ACAGGTGCCCACTCCCAGGTGCAG 
hIGHV-1/7-017-fw ATGGACTGGACCTGGAG 
hIGHV-1/7-041-fw TCCTCTTTGTGGTGGCAGCAGC 
hIGHV-2-035-fw  TCCACGCTCCTGCTRCTGAC 
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hIGHV-3-066-fw  AAGGTGTCCAGTGTGARGTGCAG 
hIGHV-3-057-fw  TAAAAGGTGTCCAGTGT 
hIGHV-4/6-066-fw CCCAGATGGGTCCTGTCCCAGGTGCAG 
hIGHV-4-022-fw  ATGAAACACCTGTGGTTCTTCC 
hIGHV-5-066-fw  CAAGGAGTCTGTTCCGAGGTGCAG 
Reverse primer 
hIGHA-111-rv  GTCCGCTTTCGCTCCAGGTCACACT 
hIGHE-140-rv  AAGGTCATAGTTGTCCCGTTGAGG 
hIGHG-137-rv  GGAAGGTGTGCACGCCGCTGGTC 
hIGHM-082-rv  GGAAGGAAGTCCTGTGCGAGGC 
 
2nd heavy PCR: 
Forward primer 
hIGHV-pan-080-fw AGGTGCAGCTGCTGGAGTCKGG 
Reverse primer 
hIGHA-076-rv  GGAAGAAGCCCTGGACCAGGC 
hIGHE-070-rv  CCAGGCAGCCCAGAGTCACGG 
hIGHG-074-rv  AGTCCTTGACCAGGCAGCCC 
hIGHM-031-rv  GGGAATTCTCACAGGAGACGA 
 
Specific heavy PCR:  
Forward primer 
5’ AgeI VH 1   CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG 
5’ AgeI VH 1-18  CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG 
5’ AgeI VH 1-24  CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG 
5’ AgeI VH 3   CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG 
5’ AgeI VH 3-9  CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG 
5’ AgeI VH 3-23  CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG 
5’ AgeI VH 3-33  CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG 
5’ AgeI VH 4   CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG 
5’ AgeI VH 4-34  CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG 
5’ AgeI VH 4-39  CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG 
5’ AgeI VH 6-1  CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG 
5’ AgeI VH 7  CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGCAATCTGG 
 
Reverse primer 
3’ SalI JH 1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG 
3’ SalI JH 3   TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG 
3’ SalI JH 6   TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG 
 
 
1st kappa PCR 
Forward primer 
5’ L-Vκ 1/2   ATGAGGSTCCCYGCTCAGCTGCTGG 
5’ L-Vκ 3   CTCTTCCTCCTGCTACTCTGGCTCCCAG 
5’ L-Vκ 4   ATTTCTCTGTTGCTCTGGATCTCTG 
 
Reverse primer 
3’ Ck 543   GTTTCTCGTAGTCTGCTTTGCTCA 
 
 
2nd kappa PCR:  
Forward primer 
5’ Pan-Vκ   ATGACCCAGWCTCCABYCWCCCTG 
 
Reverse primer 
3’ Ck494    GTGCTGTCCTTGCTGTCCTGCT 
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Specific kappa PCR:  
Forward primer 
5’ AgeI Vκ 1-5  CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC 
5’ AgeI Vκ 1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT 
5’ AgeI Vκ 1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC 
5’ AgeI Vκ 2-24  CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC 
5’ AgeI Vκ 2-28  CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC 
5’ AgeI Vκ 2-30  CTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC 
5’ AgeI Vκ 3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC 
5’ AgeI Vκ 3-15  CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC 
5’ AgeI Vκ 3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT 
5’ AgeI Vκ 4-1  CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC 
 
Reverse primer 
3’ BsiWI Jk 1/4   GCCACCGTACGTTTGATYTCCACCTTGGTC 
3’ BsiWI Jk 2  GCCACCGTACGTTTGATCTCCAGCTTGGTC 
3’ BsiWI Jk 3   GCCACCGTACGTTTGATATCCACTTTGGTC 
3’ BsiWI Jk 5   GCCACCGTACGTTTAATCTCCAGTCGTGTC 
 
 
1st lambda PCR:  
Forward primer 
5’ L-Vλ 1   GGTCCTGGGCCCAGTCTGTGCTG 
5’ L-Vλ 2   GGTCCTGGGCCCAGTCTGCCCTG 
5’ L-Vλ 3   GCTCTGTGACCTCCTATGAGCTG 
5’ L-Vλ 4/5   GGTCTCTCTCSCAGCYTGTGCTG 
5’ L-Vλ 6   GTTCTTGGGCCAATTTTATGCTG 
5’ L-Vλ 7   GGTCCAATTCYCAGGCTGTGGTG 
5’ L-Vλ 8   GAGTGGATTCTCAGACTGTGGTG 
 
Reverse primer 
3’ hCl-057   CACCAGTGTGGCCTTGTTGGCTTG 
 
2nd and specific lambda PCR:  
2nd PCR Forward primer 
hIGLV-pa1-fw CAGYCTGYSCTGACTCA 
hIGLV-pa2-fw TCCTATGAGCTGACWCAG 
 
Specific PCR Forward primer  
5’ AgeI Vλ 1   CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG 
5’ AgeI Vλ 2   CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG 
5’ AgeI Vλ 3   CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG 
5’ AgeI Vλ 4/5  CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA 
5’ AgeI Vλ 6   CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG 
5’ AgeI Vλ 7/8  CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG 
 
Reverse primer 
3’ hCl-040-XhoI   CTCCTCACTCGAGGGYGGGAACAGAGTG 
 
 
Insert check PCR: 
Forward primer 
5’ Absense   GCTTCGTTAGAACGCGGCTAC 
 
Reverse primer 
3’ IgG-Internal  GTTCGGGGAAGTAGTCCTTGAC 
3’ hCl-057  CACCAGTGTGGCCTTGTTGGCTTG 
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3’ Ck494    GTGCTGTCCTTGCTGTCCTGCT 
 
 
Table S3. Ig gene and functional features of CSP memory B cell antibodies cloned 
I, II, III and C indicate three infection and challenge time points, respectively.  
Light: K and L indicate kappa and lambda light chain, respectively. 
SHM are counted in nucleotide base pairs. 
AUC: area under the curve. 
ND: Not determined.
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L1517x0059 I 4-39 1 K 3D-20 5 M 0 0 0 0.812 0.7238 
 
L1517x0075 I 4-59 6 K 3-20 1 G2 19 4 3 4.948 0.6146 ND 0 
L1517x0105 I 5-51 4 K 4-1 1 M 0 0 0 1.273 1.392 
 
L1517x0143 I 4-59 3 K 3-20 3 M 0 0 0 0.879 1.112 
 
L1517x0146 I 3-11 4 K 3-20 2 M 0 6 0 1.242 1.236 
 
L1517x0181 I 1-18 3 K 1D-8 2 M 0 0 1 0.5103 0.4172 
L1517x0185 I 4-59 4 K 1-39 2 M 0 16 12 1.026 1.04 
L1517x0456 II 3-11 5 K 1-39 4 M 0 5 2 1.938 2.206 ND 4.6 
L1517x0604 III 1-69 3 K 4-1 1 G1 0 0 0 1.021 0.9525 
L1517x0618 III 3-33 4 K 1-12 4 M 0 7 3 5.051 5.351 1.17E-05 47.8 
L1517x0661 III 1-2 6 K 3D-15 2 M 0 5 0 0.9658 1.119 
L1517x0679 III 5-51 4 K 3-15 1 M 0 0 0 1.248 2.41 ND 0 
L1517x0683 III 4-39 5 K 1-39 5 M 0 0 0 0.7037 0.9761 
L1517x0687 III 3-23 6 K 4-1 4 M 0 0 0 0.6514 0.7386 
L1517x0692 III 3-33 4 K 4-1 1 M 0 0 0 4.665 3.101 3.52E-06 26.9 
L1517x0704 C 4-59 4 K 2-30 1 A1 0 16 9 1.01 0.9034 
L1517x0705 C 3-21 4 K 1-39 2 G2 0 5 0 1.195 1.208 
L1517x0715 C 3-23 4 K 2-28 4 M 0 19 5 0.961 0.7638 
L1517x0716 C 1-2 3 K 1-9 2 M 0 12 6 0.9323 0.8971 
L1517x0738 C 3-23 6 K 3-11 4 M 0 0 0 1.117 1.195 
 
L1426x0237 I 1-8 4 K 3-20 1 M 0 4 3 0.7789 1.005 
 
L1426x0302 I 4-61 6 K 1-39 4 M 0 0 0 0.9879 1.044 
L1426x0397 II 4-61 4 K 3-20 2 G2 0 16 12 0.537 0.526 
L1426x0725 II 4-39 6 K 2-28 4 G1 0 25 6 0.8774 0.5734 
L1426x0775 III 3-33 4 K 4-1 2 M 0 0 0 0.6182 0.6485 
L1426x0845 III 4-61 6 K 2-28 3 G1 0 7 1 0.7167 0.5105 
L1426x0864 III 3-7 4 K 2-30 2 M 0 1 0 2.711 3.095 9.13E-06 6.1 
L1426x0910 III 1-69 4 K 3-20 2 M 17 2 0 0.3353 0.365 
L1426x1003 III 4-4 6 K 2-28 1 M 0 15 5 0.6416 0.4933 
L1426x1020 III 3-23 4 K 3-15 4 M 0 0 1 0.625 1.04 
L1426x1040 III 4-30-2 5 K 3-20 2 G1 0 21 6 0.8341 0.5862 
L1426x1100 III 1-3 4 K 2-28 3 M 0 0 0 0.7704 1.008 
L1426x1186 C 3-15 4 K 3-20 4 M 0 8 9 0.6288 0.8907 
L1426x1416 C 1-8 4 K 2D-29 1 G2 3 9 12 0.5748 0.8011 
L1426x1479 C 3-30 4 K 1-16 3 M 0 0 0 0.752 0.8581 
D0835x0459 I 3-74 3 K 2-28 2 A1 33 12 13 0.8972 1.063 
D0835x0465 I 3-33 4 K 2-24 1 M 0 6 0 9.284 10.9 6.78E-06 59.3 
D0835x0473 I 3-74 3 K 2-28 2 A2 33 24 13 0.4824 0.6254 
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D0835x0507 I 3-64 4 K 1-9 3 A2 23 25 18 0.6833 0.5391 
 
D0835x0516 I 1-46 4 K 1-6 1 M 47 19 3 0.5193 0.6878 
 
L1435x1741 C 4-39 4 K 4-1 1 G1 0 26 8 10.17 7.959 1.80E-06 79 
L1435x1943 I 3-7 6 K 3-20 1 G2 28 11 9 0.8241 0.8729 
 
L1435x2011 I 3-74 3 K 2-28 2 G2 33 17 5 0.3297 0.3747 
 
L1435x2239 I 3-7 6 K 3-20 1 A2 28 15 7 0.5247 0.6119 
 
L1435x2353 II 1-2 4 K 1-39 4 M 0 15 11 1.051 1.106 
 
L1435x2354 II 3-73 6 K 1-39 1 M 0 0 0 0.6079 0.7869 
 
L1435x2690 III 3-30-3 4 K 3-11 1 M 0 4 1 7.704 6.509 7.30E-06 67 
L1435x2867 III 3-30-3 4 K 3-11 1 M 0 2 0 11.35 11.78 1.24E-05 67.7 
L1435x2887 III 3-23 4 K 4-1 1 M 0 0 0 0.7131 0.7086 
 
L1435x2889 III 3-30-3 3 K 1-17 1 M 0 1 0 0.6975 0.8907 
 
L1435x2991 III 3-33 4 K 3-20 2 M 0 0 0 4.178 5.794 1.59E-05 33.5 
L1435x2998 III 1-46 4 K 1-6 1 G2 47 19 9 0.5034 0.6399 
L1435x3008 III 3-33 4 K 1-5 1 M 0 0 0 4.643 1.988 1.18E-05 54.6 
h2088_k4041 C 3-23 4 K 1-17 4 M 0 14 2 1.668 2.646 ND 14 
L1542x0898 I 3-30-3 2 K 3-15 1 G1 0 17 9 1.016 0.7371 
L1542x1238 II 3-30 4 K 3-15 1 M 11 7 6 8.46 7.179 ND 62.4 
L1542x1286 II 3-23 4 K 1-17 4 M 0 6 0 0.4836 0.4707 
L1542x1287 II 4-4 4 K 4-1 1 A2 0 10 6 1.092 0.9613 
L1542x1369 II 3-30-3 3 K 3-15 1 M 0 2 0 3.083 1.907 ND 29.6 
L1542x1449 II 1-8 5 K 3-11 4 G3 0 6 6 1.978 1.573 
L1542x1539 III 3-30 4 K 3-15 1 M 11 7 6 7.977 6.863 ND 66.2 
L1542x1565 III 3-30 4 K 3-15 1 M 10 8 4 8.694 2.487 2.78E-06 63.5 
L1542x1571 III 3-33 4 K 4-1 1 M 0 0 0 8.262 7.863 8.19E-06 44.2 
L1542x1578 III 3-33 6 K 1-5 2 M 0 0 0 12.44 11.11 4.94E-07 69.7 
L1542x1601 III 3-33 5 K 1-5 4 M 0 0 0 2.637 2.313 1.13E-05 23.8 
L1542x1616 III 3-33 4 K 4-1 1 M 0 0 3 9.65 4.708 1.81E-06 49.3 
L1542x1633 III 3-30 4 K 3-15 1 M 10 8 4 8.192 6.651 1.83E-05 67.4 
L1542x1639 III 3-33 4 K 2-24 1 M 19 16 7 1.426 1.579 5.31E-06 
L1542x1648 III 3-30 4 K 3-15 1 M 10 8 4 7.479 5.594 1.87E-05 66.6 
L1542x1671 III 3-30 4 K 3-15 1 M 10 8 4 7.059 0.943 5.25E-06 46.9 
L1542x1690 III 3-33 4 K 2-24 1 M 20 12 5 2.672 3.787 1.03E-05 7.2 
L1542x1744 III 3-49 4 K 2D-29 2 M 0 1 0 12.75 12.2 2.63E-07 93.3 
L1542x1746 III 3-30 4 K 3-15 1 M 10 8 4 6.538 1.052 3.75E-06 37.3 
L1542x1754 III 3-30-3 6 K 3-20 2 M 0 12 6 1.803 2.473 ND 0 
L1542x1755 III 3-30 3 K 3-15 1 M 0 8 1 5.87 5.467 ND 48.5 
L1542x1761 III 3-74 4 K 4-1 2 M 0 10 5 0.7952 0.7763 
L1542x1762 III 3-33 4 K 4-1 1 M 0 8 6 9.455 6.429 2.22E-06 17.7 
L1542x1769 III 3-30 3 K 3-15 2 M 12 8 3 8.598 7.879 1.62E-05 61.5 
L1542x1773 III 3-30 4 K 3-15 1 M 11 7 6 6.316 4.212 ND 48.1 
L1542x1777 III 3-30 5 K 3-11 2 M 0 1 0 6.691 4.607 ND 56.2 
L1542x1811 III 3-30 3 K 3-15 2 M 12 7 3 7.598 6.695 1.30E-05 49 
L1542x1837 III 3-33 4 K 2-24 1 M 19 9 7 3.349 4.765 1.32E-05 7.2 
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L1542x1913 III 3-33 4 K 2-24 1 M 0 7 4 1.064 1.52 
 
L1542x1914 III 3-33 3 K 3-15 1 M 0 4 0 2.852 3.567 1.07E-05 6.3 
L1542x1933 C 3-30 4 K 1-16 4 M 0 10 2 0.602 0.6777 
 
L1542x1972 C 3-33 4 K 2-24 1 M 0 2 2 2.29 1.455 
 
L1542x2041 C 3-7 5 K 2-30 1 M 0 11 14 0.7228 0.9048 
 
L1542x2128 C 1-2 5 K 1D-43 4 M 0 16 6 0.42 0.4535 
 
L1542x2143 C 4-39 5 K 1-33 2 G1 0 19 9 0.4007 0.4317 
 
L1542x2151 C 3-33 4 K 1-5 4 M 0 0 1 11.02 9.946 6.36E-07 73.2 
L1542x2155 C 3-30 4 K 1-27 3 M 0 1 0 0.7394 0.5246 
 
L1542x2159 C 3-33 4 K 3-11 2 M 0 0 0 7.528 7.392 8.12E-06 57.7 
L1542x2180 C 3-15 4 K 3-15 4 M 0 6 0 0.55 0.6262 
 
L1542x2191 C 3-7 3 K 4-1 3 A2 22 10 6 0.3979 0.4918 
 
L1542x2193 C 3-7 3 K 4-1 3 A2 22 10 6 0.5501 0.5291 
L1542x2204 C 3-7 4 K 1-33 5 M 23 26 13 1.298 1.43 
L1542x2207 C 3-33 3 K 1-5 1 M 0 3 3 13.49 12.45 5.64E-08 94.3 
D0751x0214 III 4-30-2 4 K 1-27 4 A1 0 41 0 0.7277 0.9047 
D0751x0672 I 3-23 4 K 1-5 2 G1 7 27 26 0.9112 0.965 ND 
D0751x0701 I 3-23 4 K 1-5 2 G2 7 26 15 0.9237 0.897 ND 
D0751x0808 I 3-23 4 K 1-5 2 G2 7 28 13 1.031 0.6726 ND 
D0851x1756 II 3-48 4 K 1-33 3 M 0 0 0 0.4694 0.7221 6.5 
D0851x1789 II 1-2 4 K 1-6 4 M 0 0 0 0.4881 0.8195 0 
D0851x1790 II 4-4 3 K 3-20 2 G1 0 36 21 0.5166 0.7823 0 
D0851x1831 II 1-69 4 K 3-20 2 G1 0 21 5 0.8608 1.021 
D0851x1841 II 4-30-2 5 K 3-15 4 G1 0 23 12 0.5136 0.5684 
D0851x1877 II 3-66 6 K 1-33 4 M 0 0 0 0.4738 0.4698 
D0851x1894 II 4-59 4 K 1-5 4 M 0 0 0 0.5126 0.8587 0 
D0851x1985 II 3-23 4 K 1-5 4 A1 0 11 6 0.4404 0.437 
 
D0851x1996 II 3-9 3 K 1-5 1 M 0 0 0 0.484 0.5757 
 
D0851x2093 I 3-23 4 K 1-5 1 M 0 18 11 0.4789 0.5586 0.9 
D0851x2115 I 4-59 6 K 1-NL1 1 A1 0 28 11 0.7783 0.8589 0 
D0851x2118 I 5-a 3 K 2-28 3 M 0 0 1 0.6542 0.7711 
D0851x2168 I 3-23 5 K 1-5 1 M 0 0 0 0.9336 0.8765 
D0851x2218 I 3-30 4 K 2-30 2 M 0 0 0 0.7463 1.004 0 
D0851x2248 I 4-59 5 K 3-11 4 A2 0 23 14 0.732 0.9639 
L1471x3246 II 3-33 6 K 3-20 2 M 33 5 1 11.81 10.94 2.70E-07 74 
L1471x3374 II 3-33 6 K 3-20 2 M 33 5 1 11.4 10.36 2.85E-07 72.5 
L1471x3431 II 3-30-3 4 K 1-5 1 A2 22 43 14 0.54 0.4201 
L1471x3450 II 3-30-3 4 K 1-5 1 M 22 39 15 0.3989 0.5784 
L1471x3536 I 3-21 6 K 2-28 5 M 0 4 0 0.8453 0.8723 
L1471x3639 II 3-33 6 K 3-20 2 M 33 8 1 11.5 10.86 2.44E-07 71.9 
L1471x3683 II 3-30-3 4 K 1-5 1 A2 22 41 20 0.5861 0.8821 
L1471x3717 II 3-30-3 4 K 1-5 1 M 22 35 12 0.4909 0.8368 
L1471x3726 II 1-2 4 K 2-28 2 G1 2 6 5 13.42 3.312 1.20E-05 86.6 
L1471x3767 II 3-33 6 K 3-20 2 M 33 14 5 12.44 11.24 2.81E-07 83.5 
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L1471x3768 II 3-33 6 K 3-20 2 M 33 8 3 12.45 10.25 2.23E-07 85.4 
L1471x3788 II 3-30-3 4 K 1-5 1 A2 22 39 15 0.9357 0.9204 
 
L1471x3846 III 3-33 4 K 1-5 1 M 0 1 1 12.23 11.19 1.33E-07 97.2 
L1471x3865 III 3-30 3 K 3-20 2 M 25 3 1 13.26 12.27 5.17E-07 80.8 
L1471x3870 III 3-15 4 K 2-30 1 M 8 11 1 12.65 12.08 7.90E-08 96.9 
L1471x3896 III 3-33 6 K 3-20 2 M 33 7 5 12.98 11.9 5.20E-08 100 
L1471x3908 III 3-33 6 K 3-20 2 M 33 7 2 13.24 12.11 5.04E-08 94.1 
L1471x3919 III 4-4 6 K 3-20 2 M 57 1 2 10.55 1.375 ND 7.6 
L1471x3921 III 3-30 3 K 3-20 2 M 25 5 1 11.28 11.46 4.59E-07 74.1 
L1471x3922 III 3-33 5 K 3-11 2 M 31 2 3 11.49 10.43 1.94E-06 79.7 
L1471x3945 III 3-33 4 K 3-20 1 M 34 2 0 13.63 12.95 4.35E-08 100 
L1471x3960 III 3-33 6 K 3-20 2 M 33 10 3 13.48 11.64 2.60E-09 100 
L1471x3965 III 3-33 4 K 1-5 1 G1 27 0 2 11.6 10.85 3.13E-08 96.5 
L1471x3975 III 3-33 4 K 2-24 2 M 0 10 1 6.07 3.522 4.76E-06 
L1471x3978 III 3-33 6 K 2-24 2 G1 29 5 2 9.959 8.136 1.68E-05 57.8 
L1471x3991 III 1-46 6 K 1-5 1 M 0 0 0 0.7292 0.9019 
L1471x4031 III 3-33 4 K 3-11 4 M 0 0 0 13.5 11.18 4.85E-08 
L1471x4041 III 3-48 3 K 1-17 4 G1 36 10 1 10.96 9.588 1.46E-05 90.9 
L1471x4052 III 3-23 3 K 3-20 1 M 16 13 4 4.717 4.808 ND 46.2 
L1471x4055 III 3-48 3 K 1-17 4 A1 36 12 6 5.314 8.125 2.44E-05 84.4 
L1471x4059 III 3-33 4 K 3-11 1 A1 32 8 5 10.87 8.299 7.76E-06 59.6 
L1471x4067 III 3-15 4 K 2-30 1 M 8 12 1 13.48 10.95 7.26E-08 97.6 
L1471x4074 III 3-33 4 K 3-11 1 M 32 1 1 6.786 9.45 9.22E-06 51.6 
L1471x4087 III 3-30 3 K 3-20 2 G3 25 3 1 12.51 10.41 4.61E-07 80.9 
L1471x4092 III 3-33 4 K 3-20 1 M 34 0 0 12.51 10.96 6.24E-08 100 
L1471x4115 III 3-30 3 K 3-20 2 G1 25 4 1 12.45 10.58 4.64E-07 86.2 
L1471x4130 III 3-33 6 K 3-20 2 M 33 7 2 11.77 12.03 5.10E-08 90.5 
L1471x4137 III 3-30 6 K 1-39 2 M 0 0 0 0.9779 1.353 
 
L1471x4142 III 3-49 4 K 3-20 1 M 38 1 0 13.29 11.07 4.13E-08 99.7 
L1471x4151 III 3-33 5 K 3-11 2 M 31 2 2 12.52 10.59 3.90E-06 74.8 
L1471x4167 III 1-2 4 K 2-28 2 G1 2 6 5 13.11 3.24 7.90E-06 88.5 
L1471x4237 C 4-4 6 K 3-20 2 M 57 1 2 9.696 1.307 ND 9.3 
L1471x4239 C 3-23 3 K 3-20 1 M 16 15 5 2.713 3.186 ND 36.5 
L1471x4243 C 3-23 3 K 3-20 1 M 16 13 4 1.855 1.833 ND 13.4 
L1471x4264 C 3-15 4 K 2-30 1 M 8 12 2 11.26 11.38 1.06E-07 98.9 
L1471x4306 C 4-31 4 K 4-1 1 M 0 5 0 1.495 0.9565 
L1471x4310 C 3-33 4 K 1-5 1 G1 27 0 2 12.01 12.25 3.07E-08 100 
L1471x4332 C 3-23 4 K 4-1 1 A1 18 27 9 0.497 0.6702 
L1471x4353 C 3-48 3 K 1-17 4 M 36 10 1 8.183 10.06 1.15E-05 96.8 
L1471x4377 C 3-33 4 K 3-15 1 M 0 0 0 0.3493 0.3158 
L1471x4396 C 4-4 6 K 3-20 2 M 57 2 2 6.622 0.3291 ND 
L1471x4415 C 3-33 4 K 4-1 1 M 0 0 0 10.75 10.28 9.33E-07 65.7 
L1471x4442 C 3-23 4 K 4-1 1 A2 18 23 8 0.4266 0.4788 
L1471x4467 C 3-23 3 K 3-20 1 M 16 14 5 4.064 3.334 ND 41.6 
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L1471x4476 C 3-33 4 K 3-20 1 G1 34 1 2 11.54 10.7 3.73E-08 100 
L1471x4493 C 3-49 4 K 3-20 1 G1 38 5 1 12.07 12.22 2.46E-09 100 
L1471x4496 C 3-33 1 K 3-15 3 M 0 0 0 12.41 11.79 5.50E-06 65.7 
L1471x4498 C 3-33 4 K 3-11 2 G1 0 9 2 12.36 12.2 6.20E-10 
L1471x4533 C 3-23 4 K 4-1 1 A2 18 23 8 0.4476 0.803 
 
L1471x4560 C 3-49 4 K 3-20 1 M 38 6 3 13.43 10.72 2.37E-06 94.1 
D0972x1157 I 3-7 4 K 2-30 1 M 0 28 10 0.5702 0.6738 
 
D0972x1460 I 3-23 4 K 1-5 1 M 0 14 11 0.8998 1.063 
 
D0972x1465 I 3-48 4 K 3-15 4 A1 0 17 7 0.6861 0.913 
 
D0972x1547 II 3-33 3 K 1-5 1 M 0 5 1 11.18 7.394 1.94E-07 66.1 
D0972x1548 II 3-30-3 3 K 3-15 1 M 0 12 7 1.223 0.8995 
 
D0972x1572 II 4-59 3 K 2-28 2 M 32 1 1 13.26 0.9458 9.78E-06 81.2 
D0972x1576 II 3-30-3 3 K 3-11 1 M 8 8 0 10.26 4.737 9.41E-06 71.7 
D0972x1593 II 3-30-3 3 K 3-11 4 M 7 7 0 7.148 5.066 9.87E-06 45.9 
D0972x1620 II 4-30-2 4 K 2-30 5 G2 0 26 14 0.6419 0.938 
D0972x1647 II 3-30-3 3 K 3-11 4 M 7 2 1 7.559 5.33 9.56E-06 59.4 
D0972x1672 II 3-74 5 K 3-20 1 G4 0 28 10 0.3811 0.4916 
D0972x1765 II 4-59 3 K 2-28 2 M 32 0 0 14.15 1.749 1.00E-05 76.8 
D0972x1782 II 3-30-3 3 K 3-11 4 M 7 7 1 5.197 1.975 7.53E-06 52.7 
D0972x1783 II 3-30-3 3 K 3-11 4 M 7 0 1 7.384 5.169 8.58E-06 53.4 
D0972x1788 II 3-30-3 5 K 3-11 1 M 0 9 2 5.017 3.25 7.50E-06 42.5 
D0972x1797 II 3-33 4 K 1-5 1 G1 16 0 0 13.13 11.27 1.87E-08 81.7 
D0972x1809 II 4-61 4 K 3-11 2 A2 33 40 21 0.6694 0.6674 
D0972x1834 II 3-33 4 K 1-5 2 M 0 0 0 7.102 3.344 4.56E-06 36 
D0972x1884 II 3-33 4 K 1-5 1 M 0 0 0 0.5762 0.6022 ND 
D0972x1888 II 3-33 4 K 1-5 1 G1 15 2 0 14.42 11.34 4.59E-09 100 
D0972x1949 III 3-33 3 K 1-5 1 G1 0 4 0 12.65 9.392 2.63E-08 96.7 
D0972x1954 III 3-33 4 K 1-5 1 G1 0 7 3 13.32 9.602 1.83E-08 86.4 
D0972x1985 III 4-59 3 K 2-28 2 M 32 3 0 13.36 1.78 9.93E-06 74.7 
D0972x1987 III 3-33 3 K 1-5 3 M 13 0 0 12.37 11.65 2.20E-08 100 
D0972x1989 III 3-7 4 K 1-5 4 M 0 13 12 1.007 3.464 
D0972x1994 III 4-59 3 K 2-28 2 M 32 2 1 12.17 0.9443 9.54E-06 
D0972x2001 III 3-33 4 K 1-5 1 G1 0 0 0 13.34 10.97 
D0972x2027 III 4-39 3 K 4-1 1 M 0 8 2 0.6553 0.5225 
D0972x2032 III 3-74 5 K 2-28 4 M 0 0 0 12.86 9.403 2.38E-06 
D0972x2038 III 3-33 4 K 1D-13 4 M 0 0 0 5.404 4.446 
D0972x2073 III 3-33 4 K 1-5 2 G1 17 3 1 12.66 11.9 4.66E-09 92.2 
D0972x2100 III 3-33 3 K 1-5 3 G1 13 3 1 14.68 11.34 6.32E-09 86.7 
D0972x2102 III 3-21 5 K 1-39 1 G2 0 18 29 0.8011 0.9648 
D0972x2103 III 3-33 3 K 1-5 2 G1 0 5 0 12.14 10.01 6.92E-10 100 
D0972x2130 III 3-33 4 K 1-5 1 A1 0 13 7 0.8077 0.9099 
D0972x2140 III 3-33 5 K 1-5 1 G1 0 6 1 13.78 10.51 8.96E-10 100 
D0972x2147 III 3-33 4 K 1-5 2 G1 17 3 1 13.12 12.14 4.69E-09 100 
D0972x2151 III 3-33 2 K 4-1 1 G1 12 0 0 9.931 6.138 4.95E-06 55.8 
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D0972x2163 III 3-33 4 K 1-5 1 M 15 0 0 14 10.58 7.04E-09 100 
D0972x2164 III 3-33 3 K 1-5 1 G1 0 2 1 13.93 10.86 6.16E-10 100 
D0972x2188 III 3-33 3 K 1-5 3 M 13 0 0 12.45 10.92 2.18E-08 89.6 
D0972x2219 III 3-33 3 K 1-5 4 M 14 3 1 12.41 11.23 5.72E-09 91.5 
D0972x2235 III 3-33 2 K 4-1 1 M 12 0 0 9.846 5.599 5.19E-06 57.5 
D0972x2243 III 3-33 4 K 1-5 3 M 0 0 0 13.51 10.79 1.18E-08 100 
D0972x2248 III 3-33 4 K 1-5 1 G1 16 1 1 12.44 10.33 1.75E-08 80.8 
D0972x2249 III 4-31 4 K 4-1 1 M 25 8 3 3.419 1.68 8.41E-06 29.9 
D0972x2251 III 4-59 3 K 2-28 2 M 32 1 0 0.634 0.6896 
 
D0972x2262 III 3-33 4 K 1-5 2 G1 17 3 2 11.17 9.784 1.27E-07 89.3 
D0972x2290 III 3-33 3 K 1-5 4 M 14 0 0 10.06 5.927 1.58E-06 52.9 
D0972x2292 III 3-33 4 K 1-5 1 M 16 3 0 13.26 10.14 1.36E-08 97.5 
D0773x0980 III 3-49 4 K 1-5 1 M 18 0 0 7.227 4.038 3.43E-06 37.6 
D0773x1020 III 3-7 4 K 4-1 4 M 21 1 0 9.597 2.077 4.77E-06 70.7 
D0773x1041 III 3-23 4 K 1-5 5 M 5 5 5 10.61 2.411 8.00E-06 65.5 
D0773x1090 III 3-49 4 K 4-1 2 M 16 1 0 12.96 11.49 6.56E-07 76.8 
D0773x1204 III 3-7 4 K 4-1 4 M 21 2 2 6.622 1.45 63.8 
D0773x1210 III 3-33 3 K 1-5 1 M 9 3 4 12.81 12.52 1.14E-08 100 
D0773x1216 III 3-48 4 K 2D-29 4 A1 14 9 8 5.532 2.695 5.25E-06 
D0773x1239 III 3-49 4 K 1-5 1 M 18 0 0 7.822 8.304 3.51E-06 41 
D0773x1241 III 1-18 4 K 3-11 3 M 1 13 4 2.065 2.911 5.74E-06 0 
D0773x1259 III 3-49 4 K 4-1 2 M 16 0 0 13.73 11.21 5.00E-07 72.5 
D0773x1284 III 3-7 4 K 4-1 4 M 21 1 2 11.2 3.725 7.06E-06 
D0773x1288 III 3-33 4 K 1-39 3 G1 0 0 0 12.63 11.33 68.3 
D0773x1291 III 3-33 6 K 2-30 2 M 12 7 6 1.717 1.545 
D0773x1305 III 3-49 4 K 4-1 2 G1 16 2 5 11.93 10.54 3.78E-09 95.2 
D0773x1316 III 3-23 4 K 1-5 1 M 4 18 6 10.65 10.65 4.01E-06 59 
D0773x1320 III 3-23 4 K 1-5 1 M 4 13 6 9.334 7.948 2.12E-06 74.7 
D0773x1356 III 3-23 4 K 1-5 1 M 4 20 5 7.217 5.02 3.54E-06 69.1 
D0773x1366 II 3-23 4 K 1-5 5 M 5 2 2 11.27 1.657 9.32E-06 53.7 
D0773x1368 II 3-23 4 K 1-5 5 M 5 7 5 11.08 2.388 8.25E-06 62.1 
D0773x1372 II 3-49 4 K 2D-29 1 M 15 0 0 0.739 0.8399 
D0773x1401 II 3-23 4 K 1-5 5 M 5 13 10 11.75 2.874 4.68E-06 
D0773x1403 II 3-23 1 K 4-1 1 M 0 19 12 0.3939 0.4585 
D0773x1419 II 3-23 4 K 1-5 5 M 5 12 11 8.221 1.123 5.06E-06 41.7 
D0773x1427 II 3-23 4 K 1-5 1 M 4 15 3 7.325 7.227 4.47E-06 59.4 
D0773x1444 II 3-23 6 K 1-5 4 M 6 3 4 6.041 6.926 2.21E-06 34.3 
D0773x1450 II 3-23 4 K 1-5 1 A1 4 17 10 10.45 8.756 2.39E-06 60.5 
D0773x1463 II 3-23 4 K 1-5 5 M 5 7 9 9.354 1.688 6.37E-06 81.1 
D0773x1505 II 3-23 6 K 1-5 1 M 0 12 5 8.985 7.574 1.03E-06 
D0773x1551 II 3-23 4 K 1-5 5 M 5 9 8 10.57 3.291 3.36E-06 74 
D0773x1628 II 3-23 4 K 1-5 5 M 5 12 11 11.71 2.683 4.05E-06 82.8 
D0773x1780 II 3-33 6 K 2-30 2 M 12 9 1 0.6587 0.7955 
D0773x1810 II 3-21 6 K 1-27 4 M 0 0 0 0.6874 0.8096 
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D0873x0588 III 3-7 4 K 4-1 4 M 21 2 0 8.939 1.725 3.41E-06 
D0873x0613 III 4-39 6 K 1-17 2 G1 26 9 7 0.5126 0.5975 
 
D0873x0614 III 3-33 4 K 1-5 1 G1 0 1 1 12.97 11.2 1.95E-09 
D0873x0615 III 3-7 4 K 4-1 4 M 21 5 0 9.406 2.032 3.15E-06 
D0873x0619 III 1-18 4 K 3-11 3 M 1 13 2 3.024 2.282 7.04E-06 12.4 
D0873x0623 III 3-23 4 K 1-5 1 M 4 21 8 8.431 7.87 3.63E-06 54.9 
D0873x0647 III 3-33 6 K 1-5 1 M 10 12 3 10.88 10.88 1.99E-09 
D0873x0649 III 1-18 4 K 3-11 3 M 1 18 2 1.475 2.43 
 
D0873x0668 III 3-30-3 4 K 3-15 1 M 29 7 3 2.911 1.258 
 
D0873x0689 III 3-49 6 K 2D-29 2 M 17 3 3 11.85 10.21 2.17E-07 81 
D0873x0706 III 3-23 4 K 1-5 5 M 5 5 5 8.96 1.433 8.68E-06 51.9 
D0873x0785 III 1-18 4 K 3-11 3 M 1 18 5 0.5824 0.3885 7.02E-06 
D0873x0800 III 3-33 4 K 3-11 4 M 13 2 3 10.67 6.324 2.48E-06 60.2 
D0873x0828 III 3-30-3 4 K 3-15 1 M 29 7 3 2.392 0.9393 
D0873x0831 III 3-33 6 K 2-30 2 M 12 7 6 1.268 1.181 
D0873x0896 III 3-48 4 K 2D-29 4 A1 14 9 8 4.094 1.841 5.38E-06 
D0873x0898 III 3-23 4 K 1-5 5 M 5 18 14 12.17 2.274 2.41E-06 83.4 
D0873x0900 III 3-23 4 K 1-5 1 M 4 15 4 9.106 8.009 3.63E-06 68.2 
D0873x0905 III 3-23 4 K 1-5 1 M 4 16 2 7.334 5.722 5.26E-06 58.2 
D0873x0922 III 3-33 4 K 1-12 4 M 0 2 1 5.555 3.514 5.89E-06 19.7 
D0873x1035 II 3-23 4 K 1-5 5 M 5 9 8 9.235 2.587 3.14E-06 85.3 
D0873x1096 II 3-49 6 K 2D-29 2 M 17 0 0 12.84 11.42 4.22E-07 76.8 
D0873x1097 II 3-23 4 K 1-5 5 M 5 23 13 11.78 2.705 6.45E-06 59.2 
D0873x1158 II 3-7 4 K 1-33 1 M 0 0 0 1.023 0.9401 
D0873x1163 II 3-33 6 K 2-30 2 M 12 11 1 1.73 1.624 0 
D0873x1257 II 3-23 4 K 1-5 5 M 5 16 17 13.61 4.286 2.51E-06 81.8 
D0873x1264 II 3-23 4 K 1-5 5 M 5 7 8 11.96 2.243 6.27E-06 
D0873x1289 II 1-18 4 K 3-11 3 M 1 6 2 2.232 1.963 9.06E-07 33.5 
D0873x1308 II 3-49 6 K 2D-29 2 M 17 0 0 12.81 11.04 5.30E-07 73 
D0873x1316 II 3-23 4 K 1-5 1 M 4 15 6 10.43 9.184 2.18E-06 77.6 
D0873x1337 II 3-23 4 K 1-5 1 M 4 17 3 6.556 3.265 5.24E-06 51.7 
D0873x1342 II 3-23 4 K 1-5 5 M 5 6 8 8.979 1.592 6.33E-06 86.4 
L1517x0042 I 3-33 4 L 2-23 3 M 0 0 2 1.808 1.218 
L1517x0201 I 3-33 4 L 2-14 3 M 0 0 0 2.45 2.294 ND 0 
L1517x0212 I 3-33 4 L 1-47 2 M 0 0 0 0.6448 0.8429 
L1517x0418 II 1-46 4 L 2-8 2 M 2 19 4 1.841 1.976 ND 1.2 
L1517x0480 II 3-13 4 L 3-9 3 M 0 15 11 0.7963 0.6673 
L1517x0498 II 3-9 4 L 2-14 2 M 0 0 0 0.531 0.4273 
L1517x0521 II 4-59 4 L 1-47 3 M 0 7 5 2.609 1.938 
L1517x0552 II 3-23 4 L 1-47 2 M 0 0 0 1.046 0.6868 
L1517x0581 III 1-46 4 L 2-8 2 M 2 19 4 1.006 0.8062 
L1517x0597 III 4-39 4 L 7-43 3 M 0 0 0 0.9917 0.7692 
L1517x0610 III 3-21 4 L 6-57 3 M 0 4 1 1.123 0.9702 
L1517x0622 III 3-74 4 L 1-47 1 M 0 8 6 3.369 2.052 1.77E-07 45 
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L1517x0632 III 4-39 4 L 2-23 3 M 0 2 5 0.8283 0.8347 
 
L1517x0713 C 4-39 4 L 3-27 3 M 0 5 4 0.9995 1.18 
 
L1517x0825 C 3-23 4 L 1-44 2 M 0 6 5 0.948 0.8358 
 
L1426x0188 I 4-31 6 L 1-44 3 M 0 10 6 1.365 0.5971 
 
L1426x0222 I 4-39 4 L 3-21 2 A2 12 18 14 0.6723 0.698 
 
L1426x0453 II 3-21 3 L 1-51 2 A1 0 20 14 0.7385 0.7312 
 
L1426x0906 III 3-33 6 L 1-44 2 M 0 5 6 0.5693 0.8751 
 
L1426x1199 C 3-21 4 L 1-44 2 M 0 0 0 0.8812 0.8354 
 
L1426x1202 C 3-7 5 L 2-11 1 M 0 6 2 0.5638 0.7087 
 
L1426x1218 C 3-23 4 L 3-1 2 M 0 0 0 0.4397 0.4092 
 
L1435x1829 C 3-23 4 L 9-49 3 A1 0 19 4 0.9929 1.246 
 
L1435x1852 C 4-30-4 4 L 2-8 1 M 0 0 2 0.7484 0.9061 
 
L1435x2489 II 3-74 2 L 2-23 1 A2 36 23 6 1.458 1.406 
L1435x2546 II 1-2 3 L 3-1 2 M 0 0 0 0.653 0.8207 
L1435x2836 III 4-39 6 L 4-69 3 G2 0 5 5 0.5186 0.5424 
L1435x2873 III 3-23 5 L 1-51 3 G3 0 4 1 0.9698 1.186 
L1435x2896 III 5-51 3 L 9-49 3 G3 0 1 1 0.6158 0.6872 
L1542x1205 II 3-30-3 4 L 2-14 2 M 0 9 0 1.238 1.084 
L1542x1248 II 4-39 4 L 7-43 2 M 0 28 17 0.7612 0.6909 
L1542x1512 II 1-2 6 L 3-1 1 G1 0 2 0 1.141 1.06 
L1542x1606 III 3-30 4 L 2-14 2 M 14 1 1 6.724 6.642 1.73E-05 22.6 
L1542x1650 III 3-53 4 L 2-14 1 M 0 3 6 0.6666 0.435 
L1542x1698 III 3-23 4 L 2-14 2 M 7 8 8 0.9044 0.6334 ND 
L1542x1906 III 3-23 4 L 2-14 2 M 7 10 9 0.8669 1.144 ND 
L1542x1955 C 3-33 2 L 1-40 1 M 0 1 0 12.9 11.71 1.65E-07 87.2 
L1542x2008 C 3-23 4 L 2-14 2 M 7 10 9 1.023 1.09 ND 
L1542x2045 C 3-33 6 L 1-40 1 M 0 0 0 0.3725 0.4506 
 
L1542x2080 C 3-23 4 L 2-14 2 M 7 8 8 0.6105 0.4767 ND 
L1542x2133 C 3-23 4 L 2-14 2 M 7 11 6 7.235 2.724 1.04E-05 57.4 
L1542x2215 III 3-23 4 L 2-14 2 M 7 9 13 0.8415 0.6555 ND 
D0751x0054 III 1-3 4 L 1-47 3 M 2 4 4 0.9378 0.7449 ND 
D0751x0057 III 1-3 4 L 1-47 3 M 2 11 5 1.819 1.357 ND 
D0751x0059 III 1-3 4 L 1-47 3 M 2 12 8 1.63 1.156 ND 
D0751x0121 III 3-48 4 L 1-47 2 G1 0 1 0 6.216 5.379 ND 60.8 
D0751x0164 III 1-3 4 L 1-47 3 M 2 15 3 1.186 0.9161 ND 
D0751x0168 III 1-3 4 L 1-47 3 M 2 11 4 2.042 2.333 ND 14.5 
D0751x0169 III 1-3 4 L 1-47 3 G1 2 14 9 3.992 2.476 ND 
D0751x0175 III 1-3 4 L 1-47 3 M 2 14 6 1.907 1.483 ND 
D0751x0211 III 1-3 4 L 1-47 3 M 2 15 7 2.056 2.373 ND 25.3 
D0751x0259 III 1-3 4 L 1-47 3 M 2 11 4 2.167 1.982 ND 
D0751x0322 III 1-3 4 L 1-47 3 M 2 18 7 4.549 2.847 ND 46.4 
D0751x0353 III 1-3 4 L 1-47 3 M 2 13 9 1.911 1.172 ND 
D0751x0371 III 1-3 4 L 1-47 3 M 2 11 4 2.442 1.949 ND 29.6 
D0751x0415 II 3-74 4 L 3-1 2 M 0 8 8 0.8449 0.8916 
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D0751x0444 II 1-3 4 L 1-47 3 M 2 17 7 0.9967 1.04 ND 
D0751x0449 II 1-3 4 L 1-47 3 M 2 12 4 1.614 1.505 ND 
D0751x0500 II 4-39 3 L 1-40 1 M 16 8 3 3.892 2.183 ND 62.5 
D0751x0514 II 4-39 3 L 1-40 1 M 16 8 3 4.863 2.361 ND 69.2 
D0751x0547 II 1-3 4 L 1-47 3 M 2 10 5 1.905 2.74 ND 
D0751x0583 II 4-b 5 L 2-8 2 A1 0 24 21 0.8119 1.015 
 
D0751x0880 III 1-3 4 L 1-47 3 M 2 14 8 2.218 0.9975 ND 
D0751x0894 III 4-59 4 L 2-8 2 M 0 0 0 0.5465 0.8023 ND 4.3 
D0751x0901 III 1-3 4 L 1-47 2 M 2 14 5 3.93 1.555 ND 
D0751x0917 III 3-23 4 L 1-47 3 M 0 0 6 0.5807 0.9067 
 
6.7 
D0751x0938 III 1-2 4 L 1-51 2 M 1 25 25 1.692 2.772 ND 25.9 
D0751x0968 III 1-3 4 L 1-47 2 M 2 15 6 4.355 1.583 ND 
D0851x1569 III 3-30 6 L 2-14 2 M 0 0 0 0.7929 0.7398 
D0851x1570 III 5-51 3 L 2-14 3 G1 0 23 23 0.6657 0.7273 4.7 
D0851x1592 III 1-3 4 L 1-47 3 M 2 11 4 3.196 1.565 ND 
D0851x1665 III 1-3 4 L 1-47 3 M 2 14 8 2.319 1.163 ND 
D0851x1682 III 3-74 4 L 2-14 3 M 0 20 21 0.857 0.868 
D0851x1710 III 3-21 5 L 3-1 2 G1 0 1 2 0.6185 0.7629 1.1 
D0851x1711 III 1-3 4 L 1-47 3 M 2 16 8 2.239 1.314 ND 
D0851x1742 III 1-3 4 L 1-47 3 M 2 18 7 4.349 2.793 ND 48.9 
D0851x1758 II 1-3 4 L 1-47 3 M 2 16 6 3.167 1.59 ND 46.2 
D0851x1766 II 3-21 4 L 2-14 1 G1 0 35 25 0.4336 0.5866 0 
D0851x1767 II 3-15 6 L 3-21 3 G1 0 27 19 0.4629 0.4804 
D0851x1769 II 1-2 4 L 1-51 2 M 1 12 7 0.6988 0.9236 
D0851x1867 II 1-3 4 L 1-47 3 M 2 8 4 2.311 1.335 ND 
D0851x2031 II 3-49 6 L 2-14 1 M 0 0 0 0.6458 0.6419 
D0851x2137 I 4-59 3 L 2-11 3 M 0 0 0 0.4304 0.503 
 
D0851x2149 I 4-59 3 L 1-51 2 M 0 0 0 0.587 0.6944 
 
0.7 
D0851x2203 I 3-23 4 L 2-8 2 M 0 0 0 0.6995 0.9443 
D0851x2225 I 4-34 3 L 1-47 2 M 0 0 0 0.705 0.9024 
D0851x2235 I 4-59 4 L 2-14 2 M 0 0 2 0.4579 0.5529 0 
D0851x2249 I 4-59 2 L 1-47 3 A1 0 18 0 0.8899 1.178 
L1471x3220 II 3-73 4 L 9-49 1 M 0 0 0 0.9894 1.515 
L1471x3269 II 3-33 4 L 2-14 1 M 0 1 3 8.933 9.29 1.02E-06 69.9 
L1471x3426 II 3-23 4 L 1-47 1 M 14 13 7 13.2 12.46 1.15E-08 100 
L1471x3659 II 3-30 4 L 3-21 3 M 26 7 5 12.36 10.25 6.06E-07 84.6 
L1471x3710 II 3-7 3 L 1-51 2 M 42 7 2 9.819 7.174 7.03E-06 71.6 
L1471x3878 III 3-7 4 L 1-51 2 M 0 2 3 8.268 6.728 9.11E-06 
L1471x3933 III 3-23 4 L 1-47 1 M 14 15 7 13.22 12.02 1.69E-08 97.9 
L1471x3949 III 3-23 4 L 3-1 3 M 0 4 3 1.377 1.391 
L1471x4112 III 3-7 3 L 1-51 2 M 42 7 3 7.924 4.642 6.03E-06 69.4 
L1471x4267 C 3-23 4 L 1-47 2 M 14 2 0 11.97 10.32 4.85E-08 100 
L1471x4512 C 3-9 6 L 3-21 3 G1 53 0 1 0.5796 0.5952 
D0972x1196 I 3-30-3 4 L 4-69 3 M 9 2 2 3.862 2.383 4.54E-06 40.7 
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D0972x1271 I 3-7 4 L 2-14 1 M 0 22 8 0.3613 0.4102 
 
0 
D0972x1392 I 3-74 1 L 2-23 1 M 0 23 12 0.4888 0.6077 
 
0 
D0972x1456 I 4-30-2 3 L 1-44 1 A1 0 16 10 0.7153 0.9698 
 
D0972x1668 II 3-23 4 L 3-27 3 M 0 15 2 0.4542 0.5092 
 
D0972x1684 II 4-30-2 4 L 1-44 1 A1 0 13 8 0.5892 0.5809 
 
D0972x1694 II 3-30 4 L 9-49 1 M 11 2 2 9.853 8.463 6.46E-06 71.3 
D0972x1713 II 3-30-3 4 L 4-69 3 M 9 1 2 2.775 1.914 5.80E-06 52.6 
D0972x1791 II 3-30 4 L 9-49 1 M 11 11 3 5.135 6.019 1.03E-05 48.9 
D0972x1846 II 3-30-3 4 L 4-69 3 M 9 3 2 5.243 2.681 6.87E-06 64.2 
D0972x1928 III 3-30-3 4 L 4-69 3 M 9 3 2 3.364 1.71 4.56E-06 26.7 
D0972x2031 III 3-30-3 4 L 4-69 3 M 9 3 2 6.097 3.193 6.60E-06 34.6 
D0972x2051 III 1-69 4 L 2-23 3 M 0 8 8 0.9424 0.7766 
 
D0972x2056 III 3-23 4 L 2-11 3 M 0 18 10 1.216 1.132 
D0972x2159 III 4-39 5 L 9-49 2 A1 28 18 10 11.51 9.902 5.06E-08 86.8 
D0972x2168 III 1-2 3 L 2-23 2 M 1 0 0 0.7202 0.7922 
D0972x2296 III 4-39 5 L 9-49 2 A1 28 22 15 11.52 9.841 1.41E-07 68.7 
D0773x0982 III 3-23 4 L 1-47 2 M 28 0 0 11.38 9.135 2.42E-06 
D0773x1001 III 3-23 4 L 1-47 2 M 7 0 0 9.339 4.461 6.22E-06 73.8 
D0773x1006 III 3-23 4 L 1-47 2 M 7 0 0 9.076 5.602 5.14E-06 78.1 
D0773x1015 III 3-23 4 L 1-47 2 M 7 0 0 9.309 6.553 5.00E-06 85.9 
D0773x1096 III 3-7 4 L 4-69 3 M 22 6 1 8.611 4.817 4.52E-06 78.1 
D0773x1194 III 3-23 4 L 4-69 3 M 0 15 8 0.5218 0.9401 
D0773x1199 III 3-23 4 L 1-47 2 M 7 0 0 10.48 7.822 5.85E-06 81.8 
D0773x1233 III 3-7 4 L 4-69 3 G1 22 9 1 10.53 5.386 5.32E-07 74 
D0773x1256 III 3-74 4 L 9-49 2 M 24 0 0 12.92 12.04 4.68E-08 100 
D0773x1340 III 3-23 4 L 1-47 2 M 7 0 0 9.198 6.035 6.01E-06 81.2 
D0773x1503 II 3-21 4 L 3-21 2 M 0 0 0 0.3982 0.5058 
 
D0873x0684 III 3-74 4 L 9-49 2 M 24 0 0 11.3 11.7 3.12E-08 100 
D0873x0829 III 3-23 4 L 1-47 2 M 7 0 0 8.505 5.761 6.17E-06 88.7 
D0873x0860 III 3-23 4 L 1-47 2 M 28 1 0 10.28 6.782 2.39E-06 64 
D0873x0871 III 3-23 4 L 1-47 2 M 7 0 0 10.92 7.193 
D0873x1338 II 3-30 4 L 2-8 3 M 8 9 6 1.076 0.9934 
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